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ABSTRACT 
 
Background 
Acute myeloid leukaemia (AML) is a haematological malignancy that results from the 
malignant clonal proliferation of myeloid progenitor cells. The clinical presentation of 
AML is a consequence of bone marrow infiltration and replacement of the normal 
cellular elements in the bone marrow, resulting in a reduced production of mature 
blood cells. In the era of antiretroviral therapy, with the resultant increase in longevity 
of HIV seropositive patients, it is becoming more important for clinicians to be aware 
of the increasing incidence of solid organ and haematological malignancies in this 
group of patients. To date, there are no local studies evaluating the rare entity of AML 
occurring in patients who are infected with HIV in South Africa.  
 
Aims and Objectives 
• To describe the demographics, clinical presentation, laboratory features and 
management of patients with AML, including HIV seropositive AML from 
01/01/2005 to 31/12/2014 
• To describe the demographics, clinical presentation, laboratory features and 
management of patients with HIV seropositive AML from 01/01/1993 to 
31/12/2004, in the era of combined antiretroviral therapy not being available 
 
Patients and Methods 
A retrospective study in which patient records of adults with AML diagnosed in the 
Clinical Haematology Unit, Department of Medicine, at Chris Hani Baragwanath 
Academic hospital during the period 01/01/1993 to 31/12/2014 were reviewed. The 
data of patient’s demographics, clinical presentation, laboratory results and 
management was collected and evaluated.  
 
Results  
A total of 195 patients with AML were evaluated. This included 33 HIV seropositive 
patients with AML. However, a direct comparison was only made with 27 HIV 
seropositive patients compared to seronegative patients during the period 01/01/2005 
	 vi	
to 31/12/2014. The majority of patients were of Black African ethnicity (91.5%). 
There was a male predominance of 52% in the overall population, while the HIV 
seropositive AML subgroup showed a female predominance of 59%. The median age 
at presentation was 45 years (range 18-88 years). The clinical presentation was mainly 
with features of bone marrow failure/infiltration, manifesting with anaemia, infection 
and bleeding. The incidence of tuberculosis was significantly higher among the HIV 
seropositive AML patients. Extramedullary disease was found in 21% of patients with 
7% of patients having a myeloid sarcoma. Although HIV seropositive patients with 
AML had lower white cell counts, haemoglobin and platelet counts compared to their 
HIV seronegative counterparts, this difference was not statistically significant. The 
most common histological subtypes across the study were AML (M2) in 25% and 
AML (M3) in 22% of the patients. The most common favourable cytogenetic 
abnormalities were t(15; 17) and t(8; 21), while the most common unfavourable 
cytogenetic abnormality was t(9; 22). For induction chemotherapy, patients were 
treated with the standard “3+7” regimen, which consists of a combination of an 
anthracycline (daunorubicin) for 3 days and cytosine arabinoside for 7 days. 
Complete remission was achieved in 60% of all patients who received induction 
chemotherapy. The most common consolidation therapy given was the combination 
of an anthracycline (daunorubicin) and high dose cytosine arabinoside. 
Approximately 18% of the patients were given palliative chemotherapy. The overall 
patient outcomes were as follows: 76% of the patients demised, 18% of the patients 
were lost to follow up, and 6% were alive. 
 
Conclusion 
Acute myeloid leukaemia is the most common acute leukaemia seen in adults. AML 
in association with HIV is uncommon. To our knowledge, the current study 
encompasses the largest single center experience of this association. HIV seropositive 
patients with AML present at a younger age, with a slight female predominance. In 
general, the clinical presentation, treatment and outcome are similar to HIV 
seronegative AML, with a few exceptions. The similarities and differences are 
highlighted in this research report. It is hoped that the findings of this retrospective 
study will form the basis for more detailed and focused prospective studies on the 
association of AML in HIV seropositive individuals. 
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CHAPTER 1: LITERATURE REVIEW 
1.1. Haematopoieisis and Acute Myeloid Leukaemia 	
In the human, haematopoieisis is the process by which haematopoietic stem cells 
within the bone marrow commit to a particular cellular lineage and differentiate to 
form the mature cellular components of blood.  Haematopoetic stem cells differentiate 
into one of two major cellular lines, the myeloid or lymphoid lineages. The lymphoid 
lineage will result in the formation of mature T and B lymphocytes as well as plasma 
cells that are essential to the functioning of cellular mediated and humoral immunity. 
The myeloid lineage gives rise to mature erythrocytes, granulocytes and platelets.  
Granulocytes, which consist of neutrophils, eosinophils and basophils as well as 
monocytes, form the innate immune system. This process of cellular differentiation 
and maturation is both stimulated and regulated at a molecular level by colony 
stimulating growth factors. Cytogenetic abnormalities that occur at the level of the 
haematopoietic precursor cell can alter normal cellular proliferation and 
differentiation, resulting in an accumulation of immature myeloid or lymphoid 
precursors within the bone marrow and peripheral blood (1). The clonal proliferation 
and marrow infiltration by these abnormal precursor cells, with the inevitable 
displacement of normal haematopoetic elements, results in leukaemia. 
 
1.2.  Pathogenesis of Acute Myeloid Leukaemia 
 
Acute Myeloid Leukaemia (AML) is a result of malignant clonal proliferation of 
myeloid progenitor cells. Any genetic abnormalities that occur during and affect the 
growth and transcription factors of these cells, renders them incapable of 
differentiating into mature cells (1). These immature myeloid precursors (blasts) 
accumulate in the bone marrow and blood resulting in the reduced production of 
mature erythrocytes, neutrophils, monocytes, eosinophils, basophils and platelets.  
The clinical presentation of Acute Myeloid Leukaemia is a consequence of bone 
marrow (medullary) and tissue (extramedullary) infiltration by these blasts. 
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1.3.  Acute Myeloid Leukaemia risk factors 
 
The development of AML may be a primary (de novo) or a secondary process. Some 
well documented risk factors for the development of secondary AML include: 
previous exposure to benzene, transformation of a preceding myelodysplastic process 
or myeloproliferative neoplasm, as well as exposure to ionizing radiation (1, 2). As 
many as 10-15% of patients develop AML following exposure to a chemotherapeutic 
agent, for a primary solid organ malignancy including lymphoma. The most common 
drugs that are implicated in therapy related AML are alkylating agents, doxorubicin 
and etoposide (1).  Leukaemic cells in secondary AML have accumulated multiple 
cytogenetic and molecular abnormalities that tend to confer resistance to conventional 
chemotherapy regimens; these patients are therefore more likely to have adverse 
outcomes with a higher risk of relapse or refractory disease (1, 3).  
 
1.4.  Epidemiology 
 
Acute Myeloid Leukaemia (AML) is the most common type of acute leukaemia in the 
adult population (4). In the Western world, AML is typically a disease of middle aged 
and elderly individuals with a median age at presentation of 67 years (5). In the 
United States and Europe, the incidence has been stable at 3 to 8 cases per 100,000 
population per year (1). Historically, the disease has a higher incidence among male 
compared to female patients, with a male: female ratio of approximately 3:2 (1). 
There is currently limited population based data with regards to the epidemiology of 
Acute Myeloid Leukaemia in Africa and particularly South Africa. However, in a 
recent study of a South African cohort of 160 cases of de novo AML by Marshall et 
al., it was found that there was a slight female predominance of 52% and a younger 
median age at diagnosis of 41 years (6). 
 
1.5.  Classification of Acute Myeloid Leukaemia 
 
There are two main classification systems for Acute Myeloid Leukaemia. The most 
widely used is the French American British (FAB) classification. The FAB 
classification considers both the morphology and the cytogenetic abnormalities of the 
malignant haematopoietic cell and divides patients into subclasses, namely M0-M7.  
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The World Health Organization (WHO) classification considers the immunological, 
morphological and cytogenetic characteristics of the disease and further specifies 
AML that has evolved from pre-existing myelodysplasia, myeloproliferative 
neoplasms or therapy related AML (7, 8). New subclasses are constantly being 
defined as ongoing research discovers new genetic and molecular aberrations and the 
most recent updated WHO classification of myeloid neoplasms and acute leukaemias 
was published in 2016 (8). 
 
1.6.  Acute Myeloid Leukaemia presentation 
 
The clinical presentation of patients with AML is primarily with features of bone 
marrow infiltration and bone marrow failure due to the inability of the malignant 
blasts to differentiate into mature erythrocytes, granulocytes and platelets (1). 
Symptoms and signs include varying degrees of anaemia, bleeding and susceptibility 
to infections. Clonal blast proliferation with rapid expansion of marrow spaces may 
result in bone pain. Less commonly, malignant myeloid blasts infiltrate 
extramedullary tissues and patients may present with gum hypertrophy, organomegaly 
and skin manifestations, such as granulocytic/myeloid sarcomas. Myeloid sarcomas, 
also known as granulocytic sarcoma or chloroma, are soft tissue masses that are 
formed by aggregation of myeloid blasts in peripheral tissues. Myeloid sarcomas are 
generally rare and represent less than 1-5 % of the clinical presentation of AML (1). 
However, they may be more commonly associated with particular histological 
subtypes of AML, such as AML M2 (1).  
 
1.7.  Complications of Acute Myeloid Leukaemia 
 
Acute Myeloid Leukaemia can present with complications at the time of diagnosis. A 
high blast load and infiltration of peripheral tissues can impair blood flow, resulting in 
poor tissue perfusion. This complication of leukaemia is known as leukostasis and is 
more likely to occur in patients with extremely elevated white cell counts. Leukostasis 
may be life threatening when it occurs in the lungs, resulting in acute respiratory 
distress syndrome, and in the central nervous system. Bleeding and coagulopathy may 
be a complication of disseminated intravascular coagulopathy (DIC). This 
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complication is more commonly associated with the acute promyelocytic subtype of 
AML, AML M3 (1). The initiation of remission inducing cytotoxic therapy may be 
associated with further worsening of cytopenias and tumour lysis syndrome, 
particularly in patients presenting with markedly elevated leucocyte counts (generally 
above 200 x 109/l). 
 
1.8.  Diagnosis of Acute Myeloid Leukaemia 
 
Although a presumptive diagnosis of AML can often be made based on the clinical 
features of bone marrow failure and the presence of myeloid blasts on a peripheral 
blood specimen, the definitive diagnosis of AML is confirmed on the morphological 
assessment of a bone marrow aspirate and trephine sample. The blasts should be 
confirmed to be of myeloid origin and must account for at least 20% of the total cell 
population within the bone marrow (7, 8). In a recent review of the diagnostic criteria 
for AML it has been stated that a diagnosis of AML can be made at any blast count in 
the marrow, provided that typical cytogenetic abnormalities are demonstrated within 
the malignant cells, including t(15; 17), t(8; 21), t(16; 16) and inv(16) (2, 7, 8). 
Further investigation of immunophenotying by means of flow cytometry, in addition 
to molecular and cytogenetic testing can then be carried out to determine specific 
genetic abnormalities. This aids in further classifying the subtype of AML. 
Determining the morphological and cytogenetic subtype of AML aids in the 
diagnosis, treatment (choice of chemotherapy) and the post treatment monitoring of 
patients with AML (2).  
 
The presence of particular cytogenetic abnormalities are directly associated with 
either a good, intermediate or poor prognosis for the response to chemotherapy as 
well as the overall disease outcome (1, 9, 10). The cytogenetic abnormalities that 
confer the best prognosis and response to chemotherapy are those consisting of 
balanced fusion genes such as t(8; 21), t(15; 17) and inv(16) (2). Unfavourable 
cytogenetic abnormalities are associated with high risk for chemotherapy resistance, 
and include: t(9; 22), t(6; 9) and a complex karyotype (i.e. 3 or more chromosomal 
abnormalities occurring within one cell). These patients have lower remission rates 
and higher risk of disease relapse. Patients with genetic abnormalities that are 
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associated with intermediate risk disease show a variable response to chemotherapy 
and the prognosis in these patients may be somewhat unpredictable. Novel 
cytogenetic abnormalities such as genetic mutations in nucleophosmin-1 (NPM1), 
fms related tyrosine kinase 3 (FLT3) as well as ccaat/enhancer binding protein α 
(CEBPα) have been identified in patients with AML and are being used to aid in 
further subtyping and risk stratifying patients with AML (11). 
 
1.9.  Management of Acute Myeloid Leukaemia 
1.9.1. Supportive measures 
The supportive management of AML consists of the following: 
I. Psychosocial and educational support of the patients and their family, 
II. The transfusion of blood and blood products as and when indicated. Blood 
products should be leucocyte depleted to prevent alloimunisation in patients 
who may be potential candidates for stem cell transplantation, once remission 
has been achieved (4). 
III. The management of neutropenia and infections. Severe neutropenia manifests 
as an increased susceptibility to infections and remains an important 
complication and cause of mortality in patients undergoing chemotherapy for 
AML (2). Neutropenic patients are at risk of potentially invasive and 
disseminated infections by gram-positive and gram-negative bacteria, as well 
as fungal and atypical pathogens (1). To minimize the risk of infection, 
neutropenic measures include isolation, barrier nursing and prophylactic 
antibiotic and antifungal therapy as required.  
IV. Other general measures: these include treating and correcting electrolyte 
abnormalities, prevention of hyperuricaemia, pain management with 
analgesics and leukapharesis, where indicated. Patients who present with 
excessively elevated leucocyte counts with symptoms of leukostasis may 
require rapid lowering of the blast count with leukapharesis (12). 
In the past granulocyte transfusions were explored as a potential solution to the 
challenge of severe neutropenia, however they proved to be technically difficult to 
procure, and their therapeutic benefit remains unclear (12). The routine use of 
granulocyte colony stimulating growth factors in myeloid neoplasms is not advisable 
due to the potential risk of stimulating further proliferation of the malignant myeloid 
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clone. However, they may occasionally become necessary to treat severe systemic 
infections during the induction phase of chemotherapy (4). The advent of improved 
antimicrobial agents and safer blood transfusion practices over time have greatly 
contributed to improving the survival and outcome of patients with AML, while the 
aim of initial definitive treatment is to rapidly reduce the malignant proliferation of 
blasts and restore normal haematopoiesis using a chemotherapeutic regimen (4).  
 
1.9.2.  Specific chemotherapy 
Traditionally there are two phases of chemotherapy in the treatment of AML. The 
first phase is induction and is aimed at rapidly reducing the blast burden and inducing 
remission; the second phase is aimed at consolidating remission (once achieved), in 
order to maintain remission. Maintenance therapy is generally not administered to 
AML patients, with the exception of AML M3 (acute promyelocytic leukaemia). 
 
The induction chemotherapy protocols for AML have remained fairly constant in the 
past decade, with the rates of complete remission ranging from 50-85% (4, 13, 14). A 
standard treatment regimen consists of the combination of an anthracycline, typically 
daunorubicin at 45-50 mg/m2 given intravenously daily over 3 days with cytosine 
arabinoside at 100-200 mg/m2 given as a continuous infusion over 7 days (4, 14). In 
suitable patients who have high-risk disease and are transplant eligible, allogeneic 
stem cell transplantation should be offered as a post remission strategy. In recent 
years, the need to achieve improved rates of complete remission and patient survival 
has prompted new regimens to be considered in the treatment of AML.  
 
Dose intensification of daunorubicin up to 90 mg/m2 has been shown to improve both 
the rates of complete remission as well as overall survival without significantly 
increasing the risk of toxicity in patients treated for AML (13). This benefit was 
initially mainly seen in younger patients (< 60 years of age) with a favourable or 
intermediate risk cytogenetic profile (13, 15). However, at long term follow up, the 
benefit of dose intensification of daunorubicin is seen in all age groups and across all 
cytogenetic profiles (13, 16-18). Locally, similar responses to dose intensification 
were found during two prospective studies by Novitzky et al., conducted at the 
University of Cape Town between 1990 and 1998, where higher doses of 
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daunorubicin (up to 75 mg/m2) given during induction as well as consolidation cycles 
of chemotherapy, resulted in higher remission rates from 59% to 77% without adverse 
toxicity (19). 
 
Alternative strategies giving higher cumulative doses of daunorubicin over a two-step 
induction programme have recently been studied by the United Kingdom National 
Cancer Research Council, but has been shown to have high toxicity and unacceptable 
60-day mortality rates (13). The choice of anthracycline, in particular idarubicin 
compared to daunorubicin, has not shown any superiority in terms of remission rates 
and overall survival. In fact, idarubicin has been associated with potentially higher 
rates of marrow toxicity and longer hospital stays (4, 13). 
 
New drugs that are targeting molecular abnormalities in the malignant stem cell have 
emerged recently in the treatment of AML. In particular, anti-CD 33 monoclonal 
antibodies targeting the transmembrane receptor have been used as additional therapy 
to the conventional induction chemotherapy regimen (20). Recent results of 
gemtuzumab-ozogamycin (Mylotarg®) from the UK Medical Research Council 
(MRC) 15 trial has only shown significant improved survival in patients with a 
favourable cytogenetic profile but has had no improvement in either remission rates 
or overall survival rates (13). Higher doses of the drug are also associated with life-
threatening adverse effects such as veno-occlusive disease. This has prompted the 
need to either decrease the dose of the drug or to develop less toxic anti-CD 33 
monoclonal antibodies (13). 
 
There are a number of molecular targeted therapies that are at different stages of 
development and use in clinical trials, but are not yet generally available for use in 
standard clinical practice. For example, FLT3 tyrosine kinase inhibitors such as 
midostaurin, are being evaluated in combination with conventional chemotherapy and 
so far have shown some improvement in disease free but not overall survival rates (3). 
These novel therapies provide hope of improved remission rates and overall outcomes 
for patients with AML in the future.  
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In order to satisfy the definition of complete morphological remission, the following 
end points should be met: i) there should be no clinical evidence of disease, ii) there 
should be evidence of marrow recovery with an absolute neutrophil count more than 1 
x 109/l, as well as a platelet count of more than 100 x 109/l, and the absence of blasts 
in the peripheral blood, iii) the bone marrow should consist of no more than 5% blasts 
(this should concur with flow cytometry showing ≤ 5% blasts). In addition, there 
should be evidence of tri-lineage maturation of haematopoiesis, and no evidence of 
foci or clusters of blasts on the bone marrow trephine biopsy (1). The cytogenetic 
abnormalities that were previously present should ideally not be detectable through 
cytogenetic and molecular testing, in order to define cytogenetic remission. Minimal 
residual disease (MRD) occurs in patients who meet the remission criteria but have 
evidence of persistent disease that is detectable by flow cytometry or genetic tests 
such as quantitative polymerase chain reaction (21). The presence of MRD suggests 
that there is a subset of clonal cells that are likely resistant to chemotherapy which 
have the potential to proliferate and cause future disease relapse (22). Patients with 
MRD have a higher risk of chemo-resistant and refractory disease and therefore have 
more adverse outcomes when compared to patients who have no evidence of 
molecular disease during complete remission (2, 21, 22). MRD is becoming an 
increasingly recognized prognostic factor in stratifying patients with AML in clinical 
practice (11, 22). Once remission has been achieved, post remission treatment ideally 
aims to eradicate the disease and in so doing cure the patient. However, this is a less 
realistic goal in elderly patients, who constitute a sizeable component of the AML 
population in the Western world.  
 
The standard of care for consolidation chemotherapy in AML for patients with an 
intermediate to favourable risk profile is with cytosine arabinoside given at high doses 
of 1-3 g/m2  twice a day (14). Data from the Cancer and Leukaemia Group B (CALB) 
suggests that at least 4 cycles of consolidation chemotherapy should be given for the 
best outcome (14). In patients with an unfavourable cytogenetic profile, an allogeneic 
haematopoetic stem cell transplant instead of consolidation chemotherapy should be 
considered as soon as complete remission has been achieved. This is due to the high 
risk of future relapse in this group of patients. 
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In patients who fail to respond to conventional induction chemotherapy or relapse 
during the course of their disease, salvage chemotherapy may be indicated although 
the choice of drug regimen remains a challenge. There is yet to be a combination of 
chemotherapy that has shown superiority as salvage therapy, however, treatment with 
a purine analogue (either a cladrabine or fludarabine) based induction regimen is the 
accepted conventional therapy in fit patients (2). These drugs are not effective as 
monotherapy and are combined with cytosine arabinoside and granulocyte colony 
stimulating factor (G-CSF), as the CLAG or FLAG regimen (23). In a recent study by 
Park et al., which evaluated patients with refractory or relapsed AML, treated with 
either cladrabine or fludarabine, there was no significant difference in overall and 
disease free survival between the two drugs (23). Alternatives for salvage therapy 
include various combinations of cytosine arabinoside with agents such as 
mitoxantrone, etoposide and idarubicin. In general, the outcome for patients with 
refractory or relapsed disease is poor with less than 10% of patients achieving 
remission with salvage therapy, and allogeneic stem cell transplantation being the 
only possibility of cure (2, 3, 23, 24). 
 
As part of post remission therapy patients should ideally be considered for allogeneic 
stem cell transplantation (SCT) as this mode of definitive therapy results in the lowest 
risk for future disease relapses (13, 14, 25, 26). The limitation of allogeneic SCT, is 
the transplant related morbidity and mortality, related to myeloablation and potential 
acute or chronic graft versus host disease (26). In the South African setting, a major 
challenge is the paucity of HLA compatible donors for African patients (25). Patients 
who do not have an HLA compatible sibling or donor, can be considered for an 
autologous stem cell transplant if a matched unrelated donor transplant is not feasible.  
 
The outcome of allogeneic compared to autologous stem cell transplantation as 
consolidation therapy in AML patients was assessed as part of the Cape Town 
Regimen V (CTR-V) prospective study. The data supports the fact that the outcomes 
and relapse rates of autologous SCT were comparable to those of allogeneic SCT in 
patients with favourable to intermediate risk cytogenetics (25). Where an allogeneic 
stem cell transplant is not possible, an autologous stem cell transplant maybe an 
alternative that can be used as consolidation therapy in these patients, albeit with the 
risk of disease relapse being higher in autologous transplants. Stem cell 
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transplantation remains a scarcely available mode of therapy in resource poor settings, 
as it requires highly specialized resources and can only be performed in experienced 
specialized centers. 
1.10.  Acute Myeloid Leukaemia in the elderly 
 
Elderly patients (above the age of 60 years) with AML have a poor outcome with 
complete remission rates of less than 60% and survival rates at 5 years of 5-10% (3, 5, 
27). There are multiple patient and disease related factors that contribute to the 
mortality of older patients with AML. Older patients with AML are likely to have 
severe co-morbidities and a poor performance status resulting in a decreased capacity 
to tolerate intensive chemotherapy protocols. The elderly patient with AML also 
presents a particular therapeutic challenge as they also have a higher risk of 
demonstrating unfavourable cytogenetics that are more likely to confer resistance to 
chemotherapy, prior exposure to radiation or chemotherapeutic agents during 
treatment of a previous malignancy, and secondary AML that evolved from pre-
existing myelodysplastic disorders (27). This subset of patients are sometimes 
excluded from treatment with conventional chemotherapy, due to the risk of life-
threatening therapy related toxicity and mortality. Elderly and very elderly (above the 
age of 75 years) patients are often treated with supportive measures, less intensive or 
palliative chemotherapy. Recent new therapies that have demonstrated varying 
benefits in younger patients with AML have not extended similar benefits to older 
patients, and the median survival remains at less than 12 months (5). 
 
In AML patients who are unlikely to tolerate intensive chemotherapy, including the 
elderly, hypomethylating agents may be considered. These drugs include azacitidine 
and decitabine, have shown improved survival in preliminary trials when compared to 
conventional therapies such as low dose cytosine arabinoside, conventional intensive 
chemotherapy and supportive care in this group of patients (2, 3, 28). 
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1.11. Haematological malignancies in HIV seropositive adults 
 
The relationship between haematological malignancies and HIV infection has been 
extensively documented in relation to lymphoid malignancies. HIV seropositive 
patients with advanced retroviral disease have a higher risk of developing 
lymphoproliferative disorders, particularly high grade B-cell Non Hodgkin 
Lymphoma (NHL), such as Diffuse Large B-cell, Burkitt Lymphoma and 
Plasmablastic Lymphoma which are all acquired immune deficiency syndrome 
(AIDS) defining malignancies (29-32). These are the most common haematological 
malignancies that are diagnosed in HIV seropositive patients in South Africa (33). In 
the past decade at Chris Hani Baragwanath hospital, the number of new HIV 
seropositive patients with NHL has increased from 25 to more than 100 patients per 
year. In addition, HIV seropositivity has increased to involve more than 70% of 
patients with NHL and over 50% of patients with Hodgkin Lymphoma (HL) (33, 34). 
HIV seropositive patients with lymphoproliferative disorders are younger than their 
HIV seronegative counterparts and they frequently present with advanced and 
widespread disease, often at unusual sites (34). The predominance of extranodal and 
bulky disease occurs more frequently in HIV seropositive patients (29, 34-36). These 
features constitute poor prognostic factors that contribute to adverse outcomes and 
poorer survival rates in patients who are HIV seropositive, when compared to those 
who are HIV seronegative (34). 
 
With the introduction of highly active antiretroviral therapy (HAART) and 
combination antiretroviral therapy, the increase in the incidence of Non Hodgkin 
Lymphoma has stabilized. However, a steady increase in non-AIDS defining 
malignancies such as Hodgkin Lymphoma, has been observed in the HIV seropositive 
population (33, 37). The rise in non-AIDS defining malignancies is in part attributed 
to the improved survival of HIV seropositive patients on antiretroviral therapy. With 
regard to chronic leukaemias, it has been documented that HIV seropositive patients 
with Chronic Myeloid Leukaemia (CML) in the South African setting tend to have 
more atypical and aggressive disease (38). The association of CML with HIV 
infection is regarded as coincidental rather than causal.  
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In 2012, an estimated 35,3 million people were living with HIV globally (39). The 
highest burden of the HIV pandemic is in Sub-Saharan Africa. HIV seropositive 
patients presenting with various combinations of cytopenias is a common problem 
encountered in clinical practice in South Africa. In this setting the aetiology of the 
cytopenias are often multifactorial, including opportunistic infections, advanced 
retroviral disease, therapy related, nutritional factors, complicating malignancies and 
HIV associated myelodysplasia. Although myelodysplasia is a recognized risk factor 
for the development of AML, malignant transformation of HIV associated 
myelodysplasia to AML is a rare entity (36) 
1.12. Acute Myeloid Leukaemia in HIV seropositive adults 
 
1.12.1  Epidemiology 
The epidemiology of AML in the setting of HIV infection is not well documented 
both internationally and locally. The international literature on this topic has focused 
on a mainly homosexual, male population, with a long-standing prior diagnosis of 
HIV infection, who develop AML later in life. The demographics of these patients 
differ from the South African burden of HIV, which classically occurs in 
heterosexuals, with a slight female predominance, and therefore limits extrapolation 
of the international data to the South African population.  
 
1.12.2  Demographics 
In the published data, the majority of HIV seropositive patients with AML are male. 
In a French study by Sutton et al., 13 out of 16 patients were male who had acquired 
HIV infection through homosexual contact (40). Aboulafia et al., described similar 
results during a multicenter retrospective review of 47 HIV infected adults diagnosed 
with AML. In this study, 39 out of 47 patients were male. The median age of 
presentation of 38 years for HIV seropositive patients with AML, was younger when 
compared to their HIV seronegative counterparts (36). AML (M2) and (M4) are the 
most common histological subtypes encountered in HIV seropositive patients with 
AML (36, 40, 41).  
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1.12.3  Aetiology 
Although some patients with HIV may develop AML as a secondary process, the 
majority of HIV infected patients develop AML as a primary or de novo process with 
no identifiable risk factors. A significant risk factor for secondary AML that has been 
identified among these patients includes exposure to previous chemotherapeutic 
agents, particularly etoposide. This exposure often occurs during the treatment of a 
preceding AIDS-defining malignancy such as Kaposi’s sarcoma or High grade B-cell 
Non Hodgkin Lymphoma (36). HIV infection and its interaction with bone marrow 
elements may result in myelodysplasia, often presenting clinically as varying degrees 
of cytopenias. However, the leukaemic transformation of HIV associated 
myelodysplasia to AML remains uncommon (36). It has also been suggested that in 
the setting of impaired immune surveillance within the marrow of HIV seropositive 
patients, leukaemic cells are not detected and cleared as efficiently as they would in 
an immune-competent patient, posing as a risk factor for the potential development of 
leukaemia. 
 
1.12.4 Clinical Presentation 
The clinical presentation of AML with features of bone marrow failure/infiltration is 
universal, regardless of the HIV status. However, the diagnosis of AML may be 
delayed in patients who are HIV seropositive due to the frequent occurrence of 
cytopenias among these patients, and that may be explained by alternative causes 
(36). The presentation of HIV associated malignancies (particularly Lymphoma), has 
been well documented to follow an atypical pattern, often presenting with disease that 
is more aggressive, more advanced and manifesting at unusual sites (34). 
Extrapolating from the HIV-lymphoma data, it may be expected that HIV seropositive 
patients with AML would be more likely to have extramedullary disease. However, 
this has not been conclusively demonstrated (36, 40).  
 
1.12.5 Therapy and Outcomes   
The natural history of HIV infection results in patients acquiring significant immune 
deficiency, putting them at risk for a myriad of opportunistic infections. Additionally, 
some patients have a poor performance status and/or varying degrees of cytopenias. 
These factors provide a particular challenge with regard to the tolerance of intensive 
chemotherapy regimens in the treatment of patients who are HIV seropositive with 
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AML. HIV seropositive patients with early stage HIV disease, who are well enough to 
receive conventional induction chemotherapy with the combination of an 
anthracycline and cytosine arabinoside (“3+7” regimen – 3 days of an anthracycline 
and 7 days of cytosine arabinoside), achieve similar complete remission rates as their 
HIV seronegative counterparts (36, 40). During consolidation therapy, HIV 
seropositive patients may require dose adjustment and shortened courses of 
consolidation therapy due to a higher incidence of prolonged neutropenia after the 
administration of induction chemotherapy (40). HIV associated opportunistic 
infections, particularly tuberculosis and pneumocystis jiroveci pneumonia, may occur 
during the course of chemotherapy. Therefore, antimicrobial prophylaxis as well as 
the prompt diagnosis of established infections is an important component in the 
management of HIV seropositive patients with AML.  
 
In AML patients who successfully achieve remission, allogeneic stem cell 
transplantation is the most effective post-remission therapy in preventing future 
relapse of the disease (3, 42). In addition to maintaining remission, allogeneic stem 
cell transplantation from donors with a CCR5-d32 mutation to HIV seropositive AML 
recipients has been shown to potentially eradicate the HIV infection (43). Cysteine-
cysteine chemokine receptor 5 (CCR5) is a cellular receptor that is required for HIV 
to enter and infect various human cells. A CCR5-d32 mutation, results in a defective 
receptor that is incapable of allowing HIV to effectively enter any cell that expresses 
the abnormal receptor. This CCR5-d32 mutation occurs with highest frequency 
among the European population. There are published case reports of two patients in 
Germany, in whom the HIV remains undetectable following an allogeneic stem cell 
transplant from donor stem cells with the CCR5-d32 mutation (42, 43). This has 
resulted in the discovery that homozygosity for the CCR5-d32 mutation 
(heterozygosity to a lesser extent), confers a degree of immunity to HIV infection and 
this immunity can be transferred to a previously infected patient. 
 
The advent of HAART/cART has significantly improved the morbidity and mortality 
of HIV seropositive patients with malignancies, particularly Kaposi sarcoma and non-
Hodgkin Lymphoma (29, 35). Patients should be initiated on combination 
antiretroviral therapy as soon as the HIV seropositivity is diagnosed, and this should 
be regardless of CD4 count or clinical stage of disease, as a minimum standard of care 
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(34). Antiretroviral drugs, such as zidovudine, which have the potential to cause 
myelosuppression, are best avoided as part of combination antiretroviral therapy for 
patients with AML. Despite treatment with cART as well as chemotherapy, it has 
been shown that HIV seropositive patients with CD4 counts below 200 cells/ul or 
clinically advanced disease have higher adverse outcomes and lower disease free 
survival rates (40, 41). This occurs mainly due to the overwhelming 
immunosuppression and prolonged neutropenia as a result of the natural history of 
HIV infection as well as the effects of chemotherapy (36, 40). 
 
In the Clinical Haematology unit at CHBAH, there has been an increase in the 
number of patients with haematological malignancies who are concurrently infected 
with HIV. This includes AIDS-defining malignancies such as high grade, B-cell Non-
Hodgkin Lymphoma, HIV-associated malignancies such as Hodgkin Lymphoma and 
malignancies that have a coincidental association with HIV infection (33, 34, 38). 
Currently, AML appears to be a coincidental haematological malignancy in the 
setting of HIV infection.  In view of the paucity of information on HIV infection and 
AML in the South African population, this study was undertaken in order to evaluate 
the epidemiology, clinical presentation, treatment and outcomes of HIV seropositive 
patients with Acute Myeloid Leukaemia. 
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CHAPTER 2: PATIENTS AND METHODS 
 
2.1.  Aim 
 
To describe the profile of patients diagnosed with Acute Myeloid Leukaemia (AML) 
in the Clinical Haematology unit at Chris Hani Baragwanath Academic Hospital 
(CHBAH), including those with coexistent HIV infection from 01/01/1993 to 
31/12/2014. 
 
2.2.  Objectives 
 
The objectives of this study are: 
• To describe the demographics, clinical presentation, laboratory features and 
management of patients with AML, including HIV seropositive patients with 
AML from 01/01/2005 to 31/12/2014 
• To describe the demographics, clinical presentation, laboratory features and 
management of HIV seropositive patients with AML from 01/01/1993 to 
31/12/2004 in the era of cART not being available. 
 
2.3.  Methodology 
2.3.1. Study design 
A single center, retrospective, observational review of records was carried out of all 
adult patients with AML diagnosed in the Clinical Haematology unit at Chris Hani 
Baragwanath Academic hospital during the period 01/01/2005 to 31/12/2014 and for 
the HIV seropositive patients diagnosed with AML during the period 01/01/1993 to 
31/12/2004. 
 
2.3.2. Ethics 
• Permission to conduct this study was obtained from the Heads of department for 
Clinical Haematology and Internal Medicine as well as from the hospital 
authorities at CHBAH. 
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• Ethics approval was obtained from the Human Resources Ethics Committee 
(HREC) at the University of the Witwatersrand, certificate number M141169. 
• Patient records were reviewed retrospectively; therefore no consent was required. 
 
2.3.3. Study population and setting 
This study was conducted at Chris Hani Baragwanath Academic hospital, which is 
located in the city of Johannesburg, Gauteng province. CHBAH is a public sector, 
academic hospital that is affiliated to the University of the Witwatersrand.  It is the 
third largest hospital in the world with approximately 3000 beds and serves over 150 
000 inpatients and 500 000 outpatients every year as a referral center for the Southern 
Gauteng region. The Clinical Haematology unit sees and follows up approximately 
400 new patients per year, and approximately 450 – 600 outpatients per month. 
 
2.3.4. Inclusion criteria 
• Patients ≥ 18 years of age, diagnosed with Acute Myeloid Leukaemia 
• HIV seropositive and seronegative patients were included during the period 
01/01/2005 to 31/12/2014 and HIV seropositive patients for the period 
01/01/1993 to 31/12/2014. 
 
2.3.5. Exclusion criteria 
• Patients ≤ 18 years of age were excluded from the study. 
 
2.3.6. Data collection: 
A review of clinical records in the Clinical Haematology unit for the period 
01/01/1993 to 31/12/2014 was performed. Data from patient files was reviewed and 
collected using a data collection sheet (see Appendix A). Data included 
demographics, clinical presentation, management, outcome and follow up. Laboratory 
investigations, including bone marrow findings, were recorded using a results flow 
chart (see Appendix B). Laboratory results were collected and reviewed at diagnosis 
of AML. The permission to access these clinical records was obtained from the 
relevant Heads of Department (Clinical Haematology and Internal Medicine) as well 
as the hospital administrative authorities at CHBAH. 
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2.3.7. Sampling 
A total of 222 patients with AML were identified for the study period.  
• For 20 patients, files and patient records could not be located. These patients  
were not included for analysis, leaving 202 patients. 
• Seven patients were excluded as they were <18 years of age, leaving a total of 195 
eligible patients. 
• The remaining 195 patients included all AML patients seen during the period 
01/01/2005 to 31/12/2014, together with 6 HIV seropositive AML patients from 
01/01/1993 to 31/12/2004. 
 
2.4.  Statistical analysis 
 
A sample size calculation was carried out in order to determine whether the 
population size was appropriate and to determine if the sample size would adequately 
address the objectives of the study.  It was determined that a study population of 189 
participants was appropriate for this research.  
 
Regarding the descriptive data analysis, the categorical variables were summarized as 
percentage tabulation, frequencies and ratios. This data was represented by means of 
bar graphs and pie charts. The continuous variables were summarized by the mean 
and standard deviation, median and interquartile range, and their distribution 
illustrated by means of histograms.   
 
Regarding the association between HIV status and the study variables, this was 
carried out as follows: the Chi2 test was used to assess the relationship between HIV 
status and categorical variables, while Fisher’s exact test was used for 2 x 2 tables or 
where the requirements for the Chi2 test could not be met.  The strength of the 
associations was measured by Cramer’s V and the Phi coefficient respectively.    
 
The relationship between continuous variables and HIV status was assessed by the t-
test.  Where the data did not meet the assumptions of these tests, a non-parametric 
alternative, the Wilcoxon rank sum test was used.   The Cohen’s d for parametric tests 
and the r-value for the non-parametric tests measured the strength of the associations. 
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Survival curves were derived using Kaplan-Meier estimation. Survival curves were 
compared using Cox proportional hazards regression. Data analysis was carried out 
using SAS software (Statistical Analysis System, version 9.4 for Windows).  The 5% 
significance level was used, with a p-value of <0.05, indicating statistical 
significance. 
 
A statistician was consulted for assistance with the statistical analysis.  
 
2.5.  Study significance 
 
The management of HIV seropositive patients in the South African setting has 
become essential in clinical practice. As the survival of these patients improves with 
the advent of combination antiretroviral therapy, non-communicable diseases and 
malignancies in particular, are on the increase and are creating treatment challenges in 
the management of these patients. The prevalence of Acute Myeloid Leukaemia in 
association with HIV at the Clinical Haematology unit, CHBAH appears to be 
increasing. Although the association between HIV infection and AML is still regarded 
as being coincidental, recognition of this association has created a need for a study to 
be performed, to evaluate and to determine if there are any clinically significant 
differences in the presentation and outcomes of these patients compared to their HIV 
seronegative counterparts. This information could then be used to aid in the diagnosis 
and management of HIV seropositive patients with AML in the future and to plan 
further prospective studies to better characterize and manage this association. 
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CHAPTER 3: RESULTS 	
A total of 195 patients with Acute Myeloid Leukaemia treated at the Clinical 
Haematology unit at Chris Hani Baragwanath Academic Hospital and meeting the 
inclusion criteria were evaluated for the purpose of this study. One hundred and 
eighty nine patients with AML were evaluated for the 10-year study period 
01/01/2005-31/12/2014.  
The majority of patients with AML evaluated over this time period were HIV 
seronegative 162/189 (85.7%), and 27/189 (14.3%) were HIV seropositive.  
A further 6 HIV seropositive patients with AML were evaluated for the study period 
01/01/1993-31/12/2004 and have been included in this study as case reports. 
 
3.1.  Number of patients per year 
 
The highest number of new AML patients that were seen in a single year was in 2014 
(24 patients), and 23 new patients were seen each year in 2007, 2012 and 2013, 
respectively. Although a higher number of patients were seen in the years towards the 
latter part of the study period, a clear increasing trend in the number of AML cases 
seen is not conclusively demonstrated. The number of patients seen per year of the 
study period is summarized below in figure 3.1. 
 
	
Figure 3.1: Number of patients by year of presentation 
 
 
05
1015
2025
30
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
N
um
be
r	o
f	p
at
ie
nt
s
	 21	
3.2. Demographics of Acute Myeloid Leukaemia 
 
The majority of patients were of Black African ethnicity, i.e.173/189 (91.5%). There 
were 11/189 (5.8%) White, 1/189 (0.5%) Indian and 4/189 (2.1%) Coloured patients 
in the study population, respectively. There was an overall male predominance of 
99/189 (52.4%) of the patients, compared to 90/189 (47.6%) of female patients, with a 
male: female ratio of 1.1:1. In the HIV seronegative AML group, there was a male 
predominance of 88/162(54.3%) of patients, compared to 74/162 (45.7%) of female 
patients. In the HIV seropositive group there was a female predominance of 16/27 
(59.3%) of patients, compared to 11/27 (40.7%) of male patients, with a male: female 
ratio of 1:1.5 (see table 3.1 below).  
 
The median age at presentation across the study was 45 years  (range 18-88 years). In 
the subgroup analysis, the median age of the HIV seropositive AML group was 38 
years (IQR 28-46years). This was significantly lower than that of the HIV 
seronegative AML group of 49 years (IQR 30-63 years) with a p-value of 0.027. The 
age distribution of patients in this study is summarized in table 3.1 below. 
 
Table 3.1: Gender distribution of HIV seronegative compared to HIV 
seropositive AML patients 
Variable Overall 
N (%) 
AML patients 2005-2014 p-value 
for 
between 
group t-
test 
All HIV 
seropositive 
patients 
1993-2014 
  HIV seronegative HIV 
seropositive 
  
Number 189 162 27  33 
Males 99/189 
(52.4%) 
88/162(54.3%) 11/27 (40.7%)  
0.22 
14/33 
(42.4%) 
Females  90/189 
(47.6%) 
74/162 (45.7%) 16/27 (59.3%) 19/33 
(57.6%) 
M:F ratio 1.1:1 1.2:1 1:1.5  1:1.4 
Median age  
(*IQR) 
45 years  
(18-88 years) 
49 years (30-63 
years) 
38 years (28-46 
years) 
0.027 37 years 
(28-43 
years) 
*IQR= interquartile range 	  
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3.3.  Presenting symptoms 	
Table 3.2: Presenting symptoms of AML patients 
Symptoms Overall 
N (%) 
AML patients 2005-2014 p-value 
for 
between 
group test 
All HIV 
seropositive 
patients 
1993-2014 
  HIV 
seronegative 
patients  
N=162 
HIV 
seropositive 
patients 
N=27 
  
 
 
N=33 
Symptoms of anaemia 171 (92.4%) 148 (92.5%) 23 (92.0%) 0.67 29 (93.5%) 
Symptoms of bleeding 96 (53.0%) 84 (53.8%) 12 (48.0%) 0.67 16 (53.3%) 
Gums 49 (51.6%) 41 (49.4%) 8 (66.7%) 0.36 12 (75.0%) 
Skin 47 (49.5%) 41 (49.4%) 6 (50.0%) >0.99 6 (37.5%) 
Epistaxis 40 (42.1%) 35 (42.2%) 5 (4.7%) >0.99 7 (43.8%) 
Malaena 12 (12.6%) 11 (13.3%) 1 (8.3%) >0.99 2 (12.5%) 
Menorrhagia 11 (11.6%) 8 (9.6%) 3 (25%) 0.14 4 (25%) 
Haemoptysis 7 (7.4%) 6 (7.2%) 1 (8.3%) >0.99 1 (6.3%) 
Haematuria 4 (4.2%) 4 (4.8%) 0 >0.99 1 (6.3%) 
Haematemesis 3 (3.2%) 3 (3.6%) 0 >0.99 1 (6.3%) 
Symptoms of infection 53 (28%) 45 (27.8%) 8 (29.8%) 0.82 9 (27.3%) 
Respiratory 37 (69.8%) 30 (66.7%) 7 (87.5%) 0.41 8 (88.9%) 
Gastrointestinal 9 (17%) 8 (17.8%) 1 (12.5%) >0.99 1 (11.1%) 
Genitourinary 3 (5.7%) 3 (6.7%) 0 >0.99 0 
Skin 2 (3.8%) 2 (4.4%) 0 >0.99 0 
Musculoskeletal 2 (3.8%) 2 (4.4%) 0 >0.99 0 
Central nervous 
system  
2 (3.8%) 1 (2.2%) 0 >0.99 1 (11.1%) 
Constitutional 
symptoms 
     
Weight loss 100 (52.9%) 84 (51.9%) 16 (59.3%) 0.54 19 (57.6%) 
Fever 89 (47.1%) 72 (44.4%) 17 (63.0%) 0.096 21 (63.6%) 
Night sweats 87 (46.0%) 72 (44.4%) 15 (55.6%) 0.30 18 (54.5%) 
Bone pain 29 (16.6%) 25 (16.6%) 4 (16.7%) >0.99 5 (16.7%) 
 
The most common presenting complaints were related to symptoms of anaemia, 
which were found in 92.4% of patients. Bleeding manifestations were reported in 
53.0% of patients. In the patients presenting with bleeding, the commonest site was 
gum bleeding, found in 51.6 % of patients. Symptoms of infection were present in 
28.0% of the patients at presentation, and the commonest site of infection was the 
respiratory tract, in 69.8% of patients. There was no significant difference with regard 
to sites of bleeding or symptoms of infection between the HIV seronegative and the 
HIV seropositive patients.  
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In patients who reported the presence of constitutional symptoms, the commonest 
symptom was of loss of weight in 52.9% of patients. Fever and night sweats were 
reported 47.1% and 46.0% of patients, respectively. Bone pain was an uncommon 
symptom, being present in only 16% of patients. The presenting clinical features on 
history are summarized in table 3.2 above. 
 
3.4.  Exposure to risk factors for AML 
 
A total of 7 (3.7%) AML patients in the study (6 HIV seronegative and 1 HIV 
seropositive) had a previously documented malignancy. All of them received 
chemotherapy for a prior primary malignancy. Occupational exposure to potentially 
leukaemogenic agents was found in 10 patients; 8 of these patients were HIV 
seronegative and 2 were HIV seropositive. Among those with occupational exposures, 
5 patients worked in the mining industry while the remaining 5 patients had exposure 
to chemicals in the dry cleaning, fertilizer production, chemical engineering, 
petroleum and aluminum production industries.  
 
3.5.  HIV seropositive patients with AML 
 
During the 10-year study period 01/01/2005-31/12/2014, a total of 27 HIV 
seropositive patients were diagnosed with AML at Chris Hani Baragwanath 
Academic Hospital. Among these patients, 40% were diagnosed with HIV prior to the 
diagnosis of AML, while in 60% of the patients; the diagnosis of HIV was made 
simultaneously with the diagnosis of AML. In the patients with an antecedent 
diagnosis of HIV, all the patients were on treatment with cART and the median time 
difference between the diagnosis of HIV and the diagnosis of AML was 1.4 years 
(range of 3 months to 7 years). The mean CD4 count at presentation was 353 cells/ul 
(range of 29-1379 cells/ul). This included HIV seropositive patients who were on 
treatment with cART and those who were treatment naïve.   
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The majority of HIV seropositive patients in this study were classified as WHO 
clinical stage 1, at the time of being diagnosed with AML. The WHO clinical staging 
for the HIV seropositive patients is summarized in figure 3.2 below.  
 
	
Figure 3.2: The distribution of HIV seropositive patients by WHO (World Health 
Organization) clinical stage 	
The presence of disseminated tuberculosis (TB) was the commonest clinical criteria 
for the patients who were categorized into WHO clinical stage 4. All patients who had 
a preceding diagnosis of HIV were on combination antiretroviral therapy (cART). 
Only one of these patients had previously required a change in the drug regimen due 
to an adverse drug effect.  Among the patients that were on cART, the median 
duration on treatment was 9 months (range of 0.7-84 months). 
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3.6.  Clinical signs 
 
Table 3.3: Presenting clinical signs of AML patients  
Clinical signs Overall 
N (%) 
AML patients 2005-2014 p-value for 
between 
group t-test 
All HIV 
seropositive 
patients 
1993-2014 
  HIV 
seronegative 
N=162  
HIV 
seropositive 
N=27 
  
 
N=33 
Pallor 178 (94.2%) 153 (94.4%) 25 (92.6%) 0.66 31 (93.9%) 
Lymphadenopathy 61 (32.3%) 51 (31.5%) 10 (37%) 0.66 12 (36.4%) 
Signs of bleeding 
Ecchymosis 68 (36.0%) 59 (36.4%) 9 (33.3%) 0.83 11 (33.3%) 
Petechiae 43 (22.8%) 39 (24.1%) 4 (14.8%) 0.33 7 (21.2%) 
Purpura 43 (22.8%) 40 (24.7%) 3 (11.1%) 0.14 5 (15.2%) 
Haemorrhagic bullae 11 (5.8%) 11 (6.8%) 0 0.37 0 
Evidence of infection 
Respiratory 36 (67.9%) 27 (62.8%) 9 (90.0%) 0.14 11 (91.7%) 
Gastrointestinal 3 (5.7%) 3 (7.0%) 0 >0.99 0 
Genitourinary 8 (15.1%) 7 (16.3%) 1 (10%) >0.99 1 (8.3%) 
Skin 4 (7.5%) 4 (9.3%) 0 >0.99 0 
Musculoskeletal 2 (3.8%) 2 (4.7%) 0 >0.99 0  
Central nervous system 4 (7.5%) 3 (7.0%) 0 >0.99 1 (9.0%) 
Tuberculosis            16 (8.5%) 9 (5.6%) 7 (26.0%) 0.0018 7 (22.6%) 
Organomegaly 
Hepatomegaly 77 (40.7%) 66 (40.7%) 11 (40.7%) >0.99 13 (39.4%) 
Splenomegaly 48 (25.4%) 42 (25.9%) 6 (22.2%) 0.81 6 (18.2%) 
Abdominal mass 6 (3.2%) 5 (3.1%) 1 (3.7%) >0.99 2 (6.1%) 
Extramedullary 
Gum hypertrophy 22 (11.6%) 20 (12.3%) 2 (7.4%) 0.75 3 (9.1%) 
Myeloid sarcoma 13 (6.9%) 10 (6.2%) 3 (11.1%) 0.40 3 (9.1%) 
Skin 5 (2.6%) 4 (2.5%) 1 (3.7%) 0.54 2 (6.1%) 
 
 
On general examination, 94% of the HIV seronegative AML patients were found to 
have pallor, with a similar percentage (92.6%) of HIV seropositive patients 
manifesting with pallor. Lymphadenopathy was found in 32% of the overall 
population, the proportion of patients with lymphadenopathy was similar in the HIV 
seronegative and HIV seropositive AML patients at 31.5% and 37.0%, respectively. 
 
The most common clinically evident type of cutaneous bleeding seen was ecchymosis 
seen in 36.4% of HIV seronegative AML patients and 33.3% of HIV seropositive 
AML patients. Petechiae were present in 24.1% of HIV seronegative AML patients 
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and 14.1% of HIV seropositive patients. No significant difference in the site of 
bleeding was found between the two study populations.  
 
In this study, 53 patients representing 28.8% of the total study population had a 
clinically evident infection. Within these 53 patients, the most common site of 
infection was the respiratory tract (67.9%). Among these patients with clinically 
evident infection, only 6/53 (11.3%) had positive blood cultures. The most common 
organisms that were cultured were gram-negative bacilli, present in 5 out of the 6 
patients. In the patients with positive blood cultures: 2 patients cultured Klebsiella 
Pneumonia, 2 patients cultured Escherichia Coli, 1 patient cultured Pseudomonas 
Aeruginosa and 1 patient cultured Nocardia species.  
 
The presenting clinical signs of patients with AML are summarized in table 3.3.  
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3.6.1. Presence of Tuberculosis 
Tuberculosis was present in 16/189 (8.5%) of the patients. The proportion of patients 
with TB was higher in the HIV seropositive group 7/27 (26.0%) compared to the HIV 
seronegative group 9/162 (5.6%). This difference was statistically significant 
(p=0.0018). Of the 16 patients with TB, the site of TB infection is shown below in 
figure 3.3. In 4 patients, the diagnosis of TB was made on histology of bone marrow 
samples that were evaluated for AML. Some patients had more than one site of TB, 
hence the percentages do not add up to 100%.  The most common site and type of TB 
was pulmonary TB, in 86.7% of the patients.   
 
	
PTB=Pulmonary tuberculosis; TB abdo= Abdominal tuberculosis; TBM= Tuberculous meningitis.	
 
Figure 3.3: Tuberculosis in patients with AML 
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3.6.2. Organomegaly 
The presence of hepatomegaly was found in 77/189 (40.7%) of the overall population. 
This was represented by 66/162 (40.7%) of HIV seronegative AML patients and 
11/27 (40.7%)HIV seropositive AML patients. The proportions of patients with 
hepatomegaly were similar in both study populations. Splenomegaly was found in 
48/189 (25.4%) of the overall population; 42/162 (25.9%) in HIV seronegative 
patients and 6/27 (22.2%) in HIV seropositive patients. An abdominal mass was 
detected in 6/189 (3.2%) of the patients, with 5/162 (3.1%) being found in HIV 
seronegative and only 1/27 (3.7%) of the HIV seropositive patients. A summary of 
organomegaly is provided in figure 3.4 below. 
 
	
Figure 3.4: Organomegaly and abdominal masses in AML patients. 
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3.6.3. Extramedullary disease 
The overall incidence of extramedullary disease in this population of AML patients 
was 40/189 (21.2%). Of these patients 34/40 (85.0%) were HIV seronegative, 
comprising 20.9% of the total HIV seronegative AML group. A further 6/40 (15.0%) 
were HIV seropositive, comprising 22.2% of the HIV seropositive AML group. The 
most common site of extramedullary disease was gum hypertrophy in 22/40 (55.0%) 
of patients; 20 of these patients were HIV seronegative and 2 patients were HIV 
seropositive. A total of 13 patients presented with a myeloid sarcoma; 10 of these 
patients were HIV seronegative and 3 were HIV seropositive. The overall incidence 
of myeloid sarcomas in this study population was found to be 6.9%. There was no 
statistically significant difference in the presence of extramedullary disease between 
the HIV seronegative and HIV seropositive AML patients. A summary of the 
extramedullary manifestations of AML are provided in figure 3.5 below. 
 
 
	
Figure 3.5: Extramedullary manifestations of AML 
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3.7.  De novo (primary) and secondary AML 
 
In this study, the majority of patients with AML, i.e. 132/169 (69.8%) had de novo 
AML. The overall prevalence of secondary AML in this cohort was 57/189 (30.2%). 
Of these patients, 54 were HIV seronegative. Among the 3 HIV seropositive patients 
with secondary AML, 1 patient had chemotherapy related AML and 2 patients had 
preceding myelodysplasia. Among the 54 HIV seronegative patients with secondary 
AML, the most common pathogenesis was a preceding myelodysplastic process with 
a frequency of 26/54 (48.1%), followed by a preceding myeloproliferative disorder in 
21/54 (38.9%). Chemotherapy related AML accounted for 6/54 (11.1%) of the 
secondary AML patients and 1/54 (1.9%) of secondary AML patients evolved from a 
prior diagnosis of aplastic anaemia.  A summary of the aetiology of secondary AML 
in this study is provided in table 3.4 below. 
 
Table 3.4: De novo (primary) and secondary AML 
Primary or secondary AML Overall 
N=189 
HIV seronegative 
N=162 
HIV seropositive 
N=27 
Primary  132 (69.8%) 108 (66.7%) 24 (88.9%) 
Secondary  57 (30.2%) 54 (33.3%) 3 (11.1%) 
Myelodysplasia  26 (48.1%) 2 (7.4%) 
Myeloproliferative 
disorder 
 21 (38.9% 0 
Chemotherapy related  6 (11.1%) 1 (3.7%) 
Aplastic anaemia  1 (1.8%) 0 
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3.8. Laboratory parameters of patients with Acute Myeloid Leukaemia 
Table 3.5: Laboratory parameters of patients with AML 
Variable Category 
Overall 
AML patients 2005-2014 
p-value 
for 
between-
group 
test 
HIV seropositive 
1993-2014 HIV seronegative HIV seropositive 
 
 
N=189 
 
 
% 
 
N=162 
 
% 
 
N=27 
 
% 
 
N=33 
 
% 
 
WCC x109/l (n=188) 
<4 56 29.8% 51 31.7% 5 18.5% 
0.17 
7 21.2% 
4-11 40 21.3% 31 19.3% 9 33.3% 11 33.3% 
>11 92 48.9% 79 49.1% 13 48.1% 15 45.5% 
Haemoglobin g/dl (n=188) 
Hb <10 168 89.4% 143 88.8% 25 92.6% 0.74 30 90.9% 
Females < 12 (n=90) 90 100.0% 74 100.0% 16 100.0% - 18 94.7% 
Males <14 (n=98) 97 99.0% 86 98.9% 11 100.0% >0.99 14 100.0% 
Platelets x109/l (n=188) 
<150 164 87.2% 140 87.0% 24 88.9% 
0.77 
29 87.9% 
150-450 19 10.1% 17 10.6% 2 7.4% 3 9.1% 
>450 5 2.7% 4 2.5% 1 3.7% 1 3.0% 
MCV fl (n=181) 
<80 15 8.3% 13 8.3% 2 8.0% 
0.33 
2 6.5% 
80-100 122 67.4% 108 69.2% 14 56.0% 19 61.3% 
>100 44 24.3% 35 22.4% 9 36.0% 10 32.3% 
Sodium mmol/l (n=186) 
<135 61 32.8% 45 28.1% 16 61.5% 
0.0033 
19 59.4% 
135-145 116 62.4% 107 66.9% 9 34.6% 12 37.5% 
>145 9 4.8% 8 5.0% 1 3.8% 1 3.1% 
Potassium mmol/l (n=186) 
<3.5 36 19.4% 31 19.4% 5 19.2% 
>0.99 
7 10.9% 
3.5-5.3 146 78.5% 125 78.1% 21 80.8% 25 39.1% 
>5.3 4 2.2% 4 2.5% 0 0.0% 32 50.0% 
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Variable Category 
Overall 
AML patients 2005-2014 
p-value 
for 
between-
group 
test 
HIV seropositive 
1993-2014 HIV seronegative HIV seropositive 
 
 
N=189 
 
 
% 
 
N=162 
 
% 
 
N=27 
 
% 
 
N=33 
 
% 
 
Calcium mmol/l (n=158) 
<2.05 14 8.9% 13 9.6% 1 4.5% 
0.47 
1 4.2% 
2.05-2.56 140 88.6% 120 88.2% 20 90.9% 22 91.7% 
>2.56 4 2.5% 3 2.2% 1 4.5% 1 4.2% 
Phosphate mmol/l (n=158) 
 
0.8-1.4 111 70.3% 102 75.0% 9 40.9% 10 41.7% 
>1.4 29 18.4% 18 13.2% 11 50.0% 12 50.0% 
Albumin g/l (n=170) 
<35 74 43.5% 60 41.1% 14 58.3% 
0.25 
17 56.7% 
35-50 95 55.9% 85 58.2% 10 41.7% 13 43.3% 
>50 1 0.6% 1 0.7% 0 0.0% 0 0.0% 
Ferritin ng/ml (n=147) 
<15 1 0.7% 1 0.8% 0 0.0% 
0.034 
0 - 
15-300 19 12.9% 13 10.2% 6 31.6% 7 36.8% 
>300 127 86.4% 114 89.1% 13 68.4% 13 68.4% 
Vitamin B12 pmol/l (n=136) 
<145 8 5.9% 6 5.1% 2 10.5% 
0.30 
2 10.0% 
145-637 56 41.2% 51 43.6% 5 26.3% 5 25.0% 
>637 72 52.9% 60 51.3% 12 63.2% 13 65.0% 
Urea mmol/l (n=186) 
< 2.0 4 2.2% 3 1.9% 1 3.8% 
0.65 
1 3.1% 
2.0-7.0 130 69.9% 112 70.0% 18 69.2% 22 68.8% 
>7.0 52 28.0% 45 28.1% 7 26.9% 9 28.1% 
Creatinine umol/l (n=168) 
40-100 164 97.6% 143 99.3% 21 87.5% 0.0094 26 89.7% 
>100 4 2.4% 1 0.7% 3 12.5% 3 10.3% 
Total Bili umol/l (n=168) 
0-21 152 90.5% 132 91.7% 20 83.3% 0.25 25 83.3% 
>21 16 9.5% 12 8.3% 4 16.7% 5 16.7% 
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Variable Category 
Overall 
AML patients 2005-2014 
p-value 
for 
between-
group 
test 
HIV seropositive 
1993-2014 HIV seronegative HIV seropositive 
 
 
N=189 
 
 
% 
 
N=162 
 
% 
 
N=27 
 
% 
 
N=33 
 
% 
 
ALP U/l (n=167) 
0-120 135 80.8% 114 79.7% 21 87.5% 0.58 26 86.7% 
>120 32 19.2% 29 20.3% 3 12.5% 4 13.3% 
GGT U/l (n=167) 
0-50 92 55.1% 74 51.7% 18 75.0% 0.045 24 80.0% 
>50 75 44.9% 69 48.3% 6 25.0% 6 20.0% 
AST U/l (n=167) 
0-40 131 78.4% 113 79.0% 18 75.0% 0.60 24 80.0% 
>40 36 21.6% 30 21.0% 6 25.0% 6 20.0% 
ALT U/l (n=167) 
0-40 140 83.8% 119 83.2% 21 87.5% 0.77 27 90.0% 
>40 27 16.2% 24 16.8% 3 12.5% 3 10.0% 
Uric acid mmol/l (n=105) 
<0.2 14 13.3%  12 11.4%  2 1.9% 
 0.62 
2 12.5% 
0.2-0.35 36 34.3%  32 30.5% 4 3.8% 4 25.0% 
>0.35 55 52.4%  47 44.8% 8 7.6% 10 62.5% 
LDH U/l (n=113) 
100-200 7 6.2%  7 6.2% 0 -   - 0 - 
>200 106 93.8%  89 78.8% 17 15.0% 18 100.0% 
 
WCC= white cell count; MCV=mean cell volume; Total Bili= total bilirubin; ALP= alkaline phosphatase; GGT= gamma-glutamyl transferase; AST= aspartate 
aminotransferase; ALT= alanine aminotransferase; LDH= lactate dehydrogenase.  
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Regarding the laboratory parameters, the HIV seropositive AML patients had lower 
mean haemoglobin, platelet and albumin levels, compared to their HIV seronegative 
counterparts. These differences, however, were not statistically significant. The HIV 
seropositive AML patients were noted to have statistically significantly lower serum 
sodium (Na) and gamma glutamyl transferase (δGT) levels, compared to the HIV 
seronegative patients. The HIV seronegative group had higher levels of ferritin with 
significantly more HIV seronegative patients with ferritin levels above 300 ng/ml; this 
difference was statistically significant, with a p-value of 0.034. The HIV seropositive 
patients were more likely to have a higher serum creatinine than the HIV seronegative 
AML patients; this difference was statistically significant, with a p-value of 0.0094. 
Similar laboratory values were seen between the two groups for the following 
parameters: potassium, calcium, phosphate, vitamin B12, alkaline phosphatase, 
aspartate aminotransferase and alanine aminotransferase. A summary of the 
laboratory findings in this study are tabulated in table 3.5 above. 
 
Regarding the HIV seropositive patients with AML, the mean CD4 count at the time 
of the AML diagnosis was 353 cells/ul, with a range of 29-1379 cells/ul. There were 
11 patients (47.8%) with CD4 counts below 200 cells/ul and a smaller number of 3 
patients (13%) who had a CD4 count below 50 cells/ul. The CD4 count findings are 
tabulated in table 3.6 below. 
 
Table 3.6: CD4 counts in HIV seropositive patients with AML 
 
  
Variable	 Category		 HIV	seropositive	patients			N=23	
HIV	seropositive	patients	on	cART		N=9	
HIV	seropositive	patients	cART	naïve	N=14	CD4	cell	count	cells/ul	 >501 5 (21.7%) 2	(22.2%)	 3	(21.4%)		 351-500 5 (21.7%) 2	(22.2%)	 3	21.4%)		 201-350 2 (8.7%) 2	(22.2%)	 0		 101-200 8 (34.8%) 1	(11.1%)	 7	(50%)		 50-100 0 0	 0		 <50 3 (13.0%) 2(22.2%)	 1	(7.1%)	
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With regard to the HIV seropositive patients with AML, the mean viral load was 101 
935 RNA copies/ml. There were 4 patients who were virologically suppressed; with 2 
patients having HIV viral loads that were undetectable and a further 2 patients with 
HIV viral loads of 25 and 45 copies/ml, respectively. The HIV viral load results are 
tabulated in table 3.7 below. 
 
Table 3.7: HIV viral load in seropositive patients with AML 
 
3.9. Bone marrow assessment 
3.9.1. Bone marrow morphology: cellularity 
The marrow was hypercellular in 56.5% of patients, normocellular in 31.7% of 
patients and hypocellular in 3.1% of patients. The “other” category (8%), represents 
the proportion of samples in which cellularity could not be accurately assessed. The 
marrow cellularity is represented by category in figure 3.6 below. 
	
Figure 3.6: Bone marrow morphology by cellularity 
 
Myelodysplasia was noted in 30.2% of HIV seronegative and 25.9% of HIV 
seropositive AML patients. There was no significant difference in the presence of 
myelodysplasia in the bone marrow samples of these two patient groups. 
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3.9.2. Bone marrow morphology: Histological subtype by French-American-British 
classification 	
Table 3.8: Frequency of AML histological subtypes 
FAB 
histological 
subtype 
Overall 
N=129 
HIV 
seronegative 
N=108 
HIV 
seropositive 
N=21 
ALL HIV 
seropositive 
N=26 
M0 14 (10.9%) 12 (11.1%) 2 (9.5%) 2 (7.7%) 
M1 10 (7.8%) 10 (9.3%) 0 1 (3.8%) 
M2 31 (24.0%) 21 (19.4%) 10 (47.6%) 11 (42.3%) 
M3 29 (22.5%) 22 (20.4%) 7 (33.3%) 10 (38.5%) 
M4 22 (17.1%) 20 (18.5%) 2 (9.5%) 2 (7.7%) 
M5 14 (10.9%) 14 (12.9%) 0 0 
M6 1 (0.8%) 1 (0.9%) 0 0 
M7 8 (6.2%) 8 (7.4) 0 0 
 
The most common histological subtype of AML, found in both the HIV seronegative 
and HIV seropositive groups is AML M2 (myeloblastic with granulocytic 
maturation), in 25% of the patients, while the least common subtype of AML 
encountered was AML M6 (erythroleukaemia). The AML M3 subtype was the second 
most common histological subtype across both study groups affecting 23% of the 
overall population. The AML M2 and M3 subtypes occurred at a higher frequency 
among the HIV seropositive AML patients at 45% and 40% respectively. Subtypes 
M0 and M4 occurred with higher frequency among the HIV seronegative AML 
group.  The frequency of each histological subtype in the HIV seronegative and HIV 
seropositive AML patients are represented in table 3.8 above. 
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3.9.3. Bone marrow cytogenetics 
 
3.9.3.1. Favourable cytogenetics 	
The most common cytogenetic abnormality with a favourable prognosis that was 
found in this study population is translocation (15;17), in association with a positive 
PML-RARA gene. This was present in 97% (28/29) of the patients with AML M3 
subtype, and represents 16.8% of the total study population with documented 
cytogenetic results. In the sub-group analysis 20 out of 28 AML M3 patients with 
t(15;17) were HIV seronegative, the prevalence of t(15;17) in the HIV seronegative 
patients with AML is 14%. Eight out of 28 AML M3 patients with t(15;17) were HIV 
seropositive. The prevalence of t (15;17) in HIV seropositive patients with AML is 
33%. This difference was statistically significant with a p value =0.0034.  
 
Translocation (8;21), is associated with the RUNX1/RUNX1T1 gene. It was found in 
77%  (24/31) of the patients with AML M2 subtype, representing 14.4 % of the total 
study population with documented cytogenetic results. In the sub-group analysis 16 
out of 24 AML M2 patients with t(8;21) were HIV seronegative. The prevalence of 
t(8;21) among HIV seronegative patients with AML is 11.2%. In the HIV seropositive 
group 8 out of 24 patients with AML M2 had t(8;21). Therefore, the prevalence of 
t(8;21) among HIV seropositive patients with AML is higher at 33.3%. This 
difference is statistically significant with a p value =0.0091. Inversion (16) was the 
least common favourable cytogenetic abnormality found in only 2.4% of the patients, 
and all of these patients were HIV seronegative. 
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3.9.3.2. Unfavorable cytogenetics: 	
The most common unfavourable cytogenetic abnormality found in this study 
population was translocation (9;22), which is associated with the BCR-ABL gene. A 
deletion abnormality in chromosome 7 (7q-) occurred in 6.0% of patients. The least 
common finding was a deletion of the long arm of chromosome 5 (5q-), with a 
prevalence of 2.4% of the overall population. A summary of the cytogenetic 
abnormalities found in the AML patients is tabulated in table 3.9 below. 
 
Table 3.9: Frequency of favourable and unfavourable cytogenetic abnormalities 
in AML 
Cytogenetics Overall HIV	 p-value 
for 
between  
group test	
   seronegative seropositive	 	
  N % N % N %  
  189  162  27   
Favourable t(15;17) 28 16.8% 20 14% 8 33% 0.034 
 t(8;21) 24 14.4% 16 11% 8 33% 0.0091 
 inv (16) 4 2.4% 4 2.8% 0 0% >0.99 
Unfavourable t(9;22) 11 6.6% 11 7.7% 0 0% 0.37 
 7q- 10 6.0% 10 7.0% 0 0% 0.36 
 5q- 4 2.4% 4 2.8% 0 0% >0.99 
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3.10. Treatment 
3.10.1. Induction chemotherapy 	
In this study 81.9% of patients received induction chemotherapy.  The most common 
regimen administered was the “3+7” regimen, which consists of a combination of an 
anthracycline (daunorubicin) for three (3) days with cytosine arabinoside for seven (7) 
days. This regimen was administered to 60% of patients as induction chemotherapy. 
In 10.2% of patients the cytosine arabinoside component of induction was reduced to  
only five (5) days and combined with the standard anthracycline for three days, while 
12.2% of patients received cytosine arabinoside as a single agent. All-transretinoic 
acid (ATRA) combined with an anthracycline (daunorubicin) was administered in 
15% of patients, who had AML M3 (acute promyelocytic leukaemia). Drug regimens 
that were administered for induction chemotherapy in this study are summarized in 
figure 3.7 below. 
 
		
Figure 3.7: Chemotherapy regimens administered during induction therapy in AML 
patients 
There was a lower percentage of HIV seropositive patients (35.0%) on the 
anthracycline (daunorubicin) for 3 days and cytosine arabinoside for 7 days regimen, 
compared to HIV seronegative patients (64.6%). These findings were statistically 
significant (Fisher’s exact test; p value=0.015). 
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Similarly, there was a higher percentage of HIV seropositive patients (25.0%) on the 
anthracycline (daunorubicin) for 3 days and cytosine arabinoside for 5 days regimen, 
compared to HIV seronegative patients (7.7%). This difference was statistically 
significant (Fisher’s exact test; p value=0.034). 
3.10.2. Reinduction cycle 1 	
During the course of their treatment, 48.3% of patients required a reinduction cycle of 
chemotherapy due to either primary or secondary refractory disease. Of these patients, 
the majority (57.1%) were treated with the combination of mitoxantrone, cytosine 
arabinoside and etoposide. A further 17% of patients received a combination of  an 
anthracycline (daunorubicin) for 3 days and cytosine arabinoside for 7 days, 8.6% of 
patients received a combination of daunorubicin and cytosine arabinoside and 
etoposide. A summary of the drug regimens used in reinduction cycle 1 is shown in 
figure 3.8 below. 
 
	
Figure 3.8: Chemotherapy regimens administered during reinduction cycle 1 in AML 
patients 
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There were no significant differences in the chemotherapy regimens administered for 
the first cycle of reinduction between the HIV seronegative and HIV seropositive 
patients.  
3.10.3. Reinduction cycle 2 	
A total of 50% of the patients, who received reinduction cycle 1, failed to achieve 
remission and proceeded to reinduction cycle 2. In this group of patients the most 
common drug regimen administered in 54.3% of the patients, was a combination of 
mitoxantrone, cytosine arabinoside and etoposide. A further 17% of patients were 
treated with cytosine arabinoside as a single agent and 14% of patients received a 
combination of fludarabine and cytosine arabinoside. The standard combination of an 
anthracycline (daunorubicin) for 3 days and cytosine arabinoside for 7 days was given 
to a minority of 8.6% of patients. A summary of the drug regimens administered 
during reinduction cycle 2 is shown in figure 3.9 below. 
 
	
Figure 3.9: Chemotherapy regimens administered during reinduction cycle 2 in AML 
patients 
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while all the patients who received the anthracycline (daunorubicin) for 3 days and 
cytosine arabinoside for 5 days regimen during reinduction cycle 2, were HIV 
seropositive (5.7%). This difference was statistically significant with a p value of 
0.033. 
3.10.4. Reinduction cycle 3 	
A total of 64% of patients who had received reinduction cycle 2 went on to require a 
third cycle of induction chemotherapy during their course of treatment. In this group, 
an equal number received a combination of mitoxantrone, cytosine arabinoside and 
etoposide, to those who were given a combination of fludarabine and cytosine 
arabinoside, both with a frequency of 38%. A further 10% of patients were given 
cytosine arabinoside as single agent chemotherapy. A single patient each (4.8%) 
received daunorubicin and cytosine arabinoside for 5 days and mitoxantrone and 
cytosine arabinoside respectively. 
There were no differences in regimens given between the HIV seropositive and the 
HIV seronegative patients with AML for this cycle of chemotherapy. A summary of 
drug regimens given for this cycle of chemotherapy is shown in figure 3.10 below. 
 
	
Figure 3.10: Chemotherapy regimens administered during reinduction cycle 3 in 
AML patients 	 	
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3.10.5. Reinduction cycle 4 	
A further 32% of patients who had received reinduction cycle 3, went on to receive a 
fourth cycle of reinduction therapy during their course of treatment. This group of 
patients represented 4 % (7/189) of the total study population. Among these patients, 
5 received a combination of fludarabine and cytosine arabinoside. One patient was 
given a combination of mitoxantrone, cytosine arabinoside and etoposide and the last 
patient received a combination of daunorubicin, cytosine arabinoside and etoposide.  
 
Only 2 patients received further reinduction cycles 5 and 6. Both of them were HIV 
seronegative. One patient was given a course of azacytidine for both these cycles of 
chemotherapy. The other patient received fludarabine and cytosine arabinoside then 
cytosine arabinoside as a single agent for reinduction cycles 5 and 6, respectively.   
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3.10.6. Consolidation chemotherapy 
Consolidation cycle 1 
In this study, 64.8% of patients who achieved remission received consolidation 
chemotherapy. The most common regimen given for the first cycle of consolidation 
chemotherapy was a combination of an anthracycline (daunorubicin) and cytosine 
arabinoside at a high dose, administered 12 hourly, intravenously, for three (3) days. 
There were no significant differences in the chemotherapy regimens administered for 
the first cycle of consolidation therapy between the HIV seronegative and HIV 
seropositive patients. The frequency of regimens given for the first cycle of 
consolidation chemotherapy is summarized in figure 3.11 below. 
 
	
Figure 3.11: Chemotherapy regimens administered during consolidation cycle 1 in 
AML patients 
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Consolidation cycle 2 
Approximately 84% of patients who were successfully treated with the first cycle of 
consolidation chemotherapy proceeded to receive a second cycle of consolidation 
chemotherapy. The most common regimen administered for this cycle of 
chemotherapy was a combination of an anthracycline (daunorubicin) and high-dose 
cytosine arabinoside. There were no significant differences in the chemotherapy 
regimens administered during the second cycle of consolidation between the HIV 
seronegative and the HIV seropositive patients. The frequency of regimens 
administered for the second cycle of consolidation chemotherapy are summarized in 
figure 3.12 below. 
 
	
Figure 3.12: Chemotherapy regimens administered during consolidation cycle 2 in 
AML patients 
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Consolidation cycle 3 
A further 65% of patients successfully treated with a second cycle of consolidation 
chemotherapy, proceeded to receive a third cycle of consolidation chemotherapy. The 
most common regimen administered for this cycle of chemotherapy was a 
combination of an anthracycline (daunorubicin) and high-dose cytosine arabinoside. 
This regimen was administered in 31.4% of patients. There were no significant 
differences in the chemotherapy regimens administered during the third cycle of 
consolidation between the HIV seronegative and the HIV seropositive patients. The 
frequency of regimens administered for the third cycle of consolidation chemotherapy 
are summarized in figure 3.13 below. 
 
	
Figure 3.13: Chemotherapy regimens administered during consolidation cycle 3 in 
AML patients 
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Consolidation cycle 4 
A total of 54% of patients reached consolidation cycle 4, during their initial 
chemotherapy course. The most common regimen administered for this cycle of 
chemotherapy was a combination of anthracycline (daunorubicin) and high dose 
cytosine arabinoside. This regimen was administered in 38% of patients who received 
consolidation cycle 4 chemotherapy. There were no significant differences in the 
chemotherapy regimens administered during this cycle of consolidation between the 
HIV seronegative and the HIV seropositive patients. 
 
3.11. Maintenance chemotherapy 	
Approximately 9.9% (18/182) of the total study population received maintenance 
chemotherapy. All of these patients had AML M3 (acute promyelocytic leukaemia). 
The drug regimen administered as maintenance chemotherapy in all of these patients 
was a combination of all-transretinoic acid (ATRA), mercaptopurine and 
methotrexate. The administration of maintenance chemotherapy was similar between 
the HIV seronegative and the HIV seropositive patients.  
 
3.12. Palliative chemotherapy 	
Among patients diagnosed with AML, 36/189 (19%) were treated with palliative 
chemotherapy. In this group of patients, 32/36 (89%) received oral thioguanine at a 
dose of 40 mg daily while 11% (4/36) of the patients received low dose intravenous 
cytosine arabinoside. 
 	  
	 48	
3.13. Outcomes 
3.13.1. Remission 
In this study, 60.7% of patients achieved remission after the first cycle of induction 
chemotherapy, the remaining 39.3% of patients failed to achieve remission after the 
first cycle of chemotherapy. In the subgroup analysis, among the patients who 
successfully achieved remission, 62.5% were HIV seronegative and 37.5% were HIV 
seropositive. This difference was close to, but did not achieve statistical significance, 
with a p-value of 0.054. Of the patients who achieved remission, 30% had confirmed 
relapse of their disease and later required a second course of induction chemotherapy. 
Following a second course of induction chemotherapy, only 24% of patients achieved 
a remission and 45% of these patients who achieved a remission suffered a second 
relapse during the course of their disease. 
 
3.13.2. Patient status at follow up 
A total of 76% (144/189) patients in this study demised with 132 patients having died 
from AML, while in 12 patients the cause of death was unknown. The number of 
patient who were alive was 5.8% (11/189). Among the patients who were alive, 10 
patients were in remission while 1 patient was alive with confirmed disease relapse.  
In the subgroup analysis, the numbers of demised patients were similar between the 
HIV seronegative (75%) and HIV seropositive patients (81%). The proportion of 
patients who were alive in the HIV seronegative (25%) and the HIV seropositive 
(19%) groups were also similar. There were 18% (34/189) of patients who were lost 
to follow up.  The status of disease at follow up is summarized in figure 3.14 below.  
	
Figure 3.14: Disease status at follow up 
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3.13.3. Causes of death in patients with AML 
Regarding the patients who demised, the most common cause of death was an 
infectious complication; this occurred in 81% of patients who demised. There was no 
difference in the occurrence of infection as a cause of death between the HIV 
seronegative and HIV seropositive patients with a p-value of 0.43. Haemorrhage was 
the cause of death in 15% of patients. There was no difference between the HIV 
seronegative and the HIV seropositive patients with a p-value of 0.30. Disseminated 
intravascular coagulopathy (in the absence of clinical evidence of infection) resulted 
in death in 8% of patients. There was no difference between HIV seronegative and 
HIV seropositive patients, with a p-value of 0.16. In some patients more than one 
event was documented as the cause of death, therefore the total percentages do not 
add up to 100%. The “other “category represents death events that were independent 
of the AML diagnosis.  The prevalence of the different death events is summarized in 
figure 3.15 below. 
	
Figure 3.15: Causes of death in patients with AML 
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3.13.4. Lost to follow up 
In this study, 34 patients were lost to follow up, with 30 patients being from the HIV 
seronegative AML group. The disease status of the lost to follow up patients, as 
documented at the last clinic visit was as follows: 44% of patients were in remission, 
38% of patients had refractory disease, and a further 9% of patients had either 
confirmed or suspected disease relapse. The distribution of disease status in patients 
that were lost to follow up is shown in figure 3.16 below. 
	
LTFU= lost to follow up 
Figure 3.16: Patients lost to follow up by disease status at last clinic visit 	  
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3.14. Refractory disease 
 
In this study, 38% (70/189) of the patients had disease that was refractory to 
chemotherapy. Among these patients, 59% (41/70) had never achieved remission at 
any point during the course of treatment due to primary refractory disease, while 41% 
of patients had secondary refractory disease. The patients with secondary refractory 
disease had achieved remission at some point during the course of treatment only to 
relapse later and have persistent disease despite subsequent cycles of chemotherapy. 
In the subgroup analysis of patients with refractory disease, 82.9% (58/70) were HIV 
seronegative, accounting for 36.7% of the HIV seronegative AML population. This is 
compared to 17.1% (12/70) patients who were HIV seropositive, accounting for 
44.4% of the HIV seropositive study population. This difference in refractory disease 
between the HIV seronegative and the HIV seropositive patients was not statistically 
significant with a p-value of 0.39.  
The proportion of primary to secondary refractory disease is represented n figure 3.17 
below. 
 
	
Figure 3.17: Frequency of primary versus secondary AML 
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3.15. Survival 
 
The overall median survival was 0.4 years, (95% confidence interval: 0.2-0.7 years). 
There was no significant difference in survival between the HIV seronegative and 
HIV seropositive patients (p-value of 0.40). The survival curve is shown in figure 
3.18 below. 
 
	
Figure 3.18: Survival of HIV seronegative and HIV seropositive patients with AML 
The 1-year survival rate is 32.5% and by 5 years, the probability of survival drops to 
6.5%. The survival estimates for 6 months, 1 year, 3 years and 5 years, together with 
their 95% confidence intervals, are presented in table 3.10 below. 
Table 3.10: Annual survival rates of patients with AML 
Time (years) Survival (%) 95% CI for survival (%) 
0.5 47.2% 39.7%-54.4% 
1 32.5% 25.4%-39.9% 
3 10.9% 5.8%-17.7% 
5 6.5% 2.5%-13.2% 
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When the survival time is adjusted to exclude patients with early mortality within 0-3 
months of being diagnosed with AML, the median survival time was 1.4 years (95% 
confidence interval: 0.9-1.9 years). There was no significant difference in survival 
between the HIV seronegative and HIV seropositive patients, with a p value of 0.98.  
The survival curve is shown in figure 3.19 below. 
 
	
Figure 3.19: Survival of HIV seronegative and HIV seropositive patients with AML, 
excluding patients with early mortality (within 0-3 months of diagnosis) 
The survival estimates for 6 months, 1 year, 3 years and 5 years, together with their 
95% confidence intervals, are presented in table 3.11 below. 
Table 3.11: Annual survival rates in patients with AML, excluding patients with 
early mortality (within 0-3 months of diagnosis) 
Time (years) Survival (%) 95% CI for survival (%) 
0.5 86.7% 77.7%-86.7% 
1 60.1% 48.6%-60.1% 
3 20.3% 10.8%-20.3% 
5 12.2% 4.6%-12.2% 
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3.16. Case reports 	
For the study period 01/01/1993-31/12/2004 there were 6 HIV seropositive patients 
with AML who were evaluated separately as a case series. 
3.16.1. Patient 1 
A 22-year-old male, employed as a petrol attendant, was initially admitted in June of 
1993 with a 2-week history of symptoms of anaemia, significant loss of weight and 
night sweats. Clinical examination revealed the presence of shotty generalized 
lymphadenopathy, oral candidiasis and a mild hepatomegaly with no splenomegaly. 
The patient was also newly diagnosed with HIV with a CD4 that represented 10% of 
the total lymphocyte count as well as a CD4:CD8 ratio of 0.77:1. The initial full blood 
count (FBC) showed a white cell count (WCC) of 0.53 x109/l, haemoglobin (Hb) of 
6.6 g/dl and a platelet count of 25 x109/l. The bone marrow aspirate and trephine 
biopsy revealed the presence of a hypercellular marrow with approximately 75-80% 
myeloblasts. The myeloperoxidase reaction was negative. The patient was diagnosed 
with an undifferentiated acute myeloid leukaemia (AML MO).  
 
The patient was treated with mitoxantrone. The response to chemotherapy however 
was poor and short lived with the patient developing cytopenias complicated by 
worsening nosocomial infections and haemorraghic varicella zoster. He survived for 
only one month following diagnosis with the date of death reported as July of 1993. 
He was never initiated on antiretroviral therapy. 
 
3.16.2. Patient 2 
A 37-year-old female who was known to be HIV seropositive, presented in May of 
1994 with a 2-week history of nausea, vomiting and diarrhea, combined with loss of 
weight, night sweats and a dry cough. She was diagnosed with HIV eight months 
prior to this presentation (in September of 1993). Her risk factors for HIV 
transmission included previous transfusions for anaemia. She had never been treated 
with antiretroviral drugs. Clinical examination revealed the presence of oral 
candidiasis, shotty cervical and inguinal lymphadenopathy, gum hypertrophy and a 4 
cm hepatomegaly and no splenomegaly. The initial FBC showed a high WCC of 24 
x109/l with 60% myeloblasts demonstrated on the peripheral blood smear, 
haemoglobin of 5.9 g/dl and a platelet count of 13 x109/l. The bone marrow aspirate 
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and trephine biopsy showed extensive marrow infiltration by an acute leukaemia with 
approximately 89% of blasts. The myeloperoxidase reaction was positive in 
occasional mononuclear cells. The patient was diagnosed with AML (M1) with a 
normal XY karyotype. 
 
The patient received an induction regimen that comprised of cytosine arabinoside. 
There was a poor response to chemotherapy, with a minimal decrease in the 
peripheral blast percentage from 60% to 44%. The patient demised 5 days later from 
progressive leukaemia. 
 
3.16.3. Patient 3 
A 38-year-old male was diagnosed with AML (M2) in June of 1994. He was also 
diagnosed with HIV during this admission. He received induction chemotherapy with 
mitoxantrone, successfully achieving remission. He was only given a single cycle of 
consolidation chemotherapy with mitoxantrone. He was never initiated on 
antiretroviral therapy. His follow up was erratic due to multiple periods of defaulting, 
which was mainly due to financial constraints and he was lost to follow up for a 
period of 5 months. The patient presented in May of 1995 with relapse. At relapse, he 
had fever, a productive cough, loss of weight, night sweats and symptoms of anaemia. 
His blood cultures were positive for a gram-negative bacillus. He was started on 
intravenous antibiotics and neutropenic measures. The FBC on this admission 
revealed a WCC of 3.8 x109/l, haemoglobin of 6 g/dl, a platelet count of 10 x109/l and 
peripheral blood blast percentage of 89%. The patient was given a second course of 
induction chemotherapy with mitoxantrone, but he failed to achieve a remission. A 
third cycle of induction chemotherapy was given with a combination of etoposide and 
cytosine arabinoside, which again failed to induce remission.  
 
The patient was counselled regarding his prognosis but opted to have ongoing 
intravenous chemotherapy. Salvage chemotherapy in the form of cytosine arabinoside 
was given, however the patient’s clinical condition continued to deteriorate. He had 
severe cytopenias requiring daily transfusion of blood products. He eventually 
succumbed to severe hospital acquired pneumonia in November of 1995, a total of 17 
months after he was initially diagnosed with AML. 
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3.16.4. Patient 4 
An 18-year-old female who initially presented to the surgical unit with a 3-day history 
of haematemesis, malaena stools, bleeding gums and epistaxis in February of 1995. 
On clinical examination, she was noted to be pale with significant axillary 
lymphadenopathy but no hepatosplenomegaly. The FBC on admission showed a 
WCC of 2.71 x109/l, haemoglobin of 9.2 g/dl and a platelet count of 434 x109/l The 
INR was 1.05. The bone marrow aspirate and trephine biopsy (BMAT) showed a 
hypercellular marrow with 1% blasts and 5% promyelocytes. The myeloperoxidase 
reaction was strongly positive. On cytogenetic assessment, a translocation (15; 17) 
was found and a diagnosis of acute promyelocytic leukaemia was made. During this 
admission she was also newly diagnosed with HIV. The baseline CD4 count was 410 
cells/ul. 
 
The patient was started on all-transretinoic acid as a single agent and responded well 
to the treatment. The repeat BMAT performed in March of 1995 showed 
morphological remission. She was never treated with antiretroviral therapy. The 
patient was subsequently discharged to follow up. However, she was lost to follow up 
since March 1995.  
3.16.5. Patient 5 
A 30-year-old male presented in June of 2000 with a 1-month history of a sore throat, 
gum bleeding and symptoms of anaemia. On clinical assessment he was noted to have 
features of a purulent tonsillitis with associated pharyngitis. His FBC revealed a WCC 
70 x109/l, haemoglobin of 6.1 g/dl and a platelet count of 33 x109/l. The peripheral 
smear had 90% abnormal promyelocytes. He was newly diagnosed with HIV and his 
CD4 count was 554 cells/ul and HIV viral load was 37 300 copies/ml. A bone marrow 
aspirate and trephine revealed a marrow that was extensively infiltrated by 89% 
promyelocytes, morphologically in keeping with acute promyelocytic leukaemia, 
AML (M3). Fluorescent-in-situ hybridization (FISH) confirmed the presence of 
translocation (15; 17). The patient was given induction chemotherapy with a 
combination of daunorubicin, cytosine arabinoside and all-transretinoic acid (ATRA). 
A follow up bone marrow assessment confirmed morphological remission and FISH 
was negative for the PML-RARA gene. A total of 3 cycles of consolidation 
chemotherapy were given using the same chemotherapy combination as used during 
induction. The patient was initiated on cART by the infectious disease team. 
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The patient was well for a period of 3 months until he suffered a relapse of APL in 
January 2001. On this presentation he had a CD4 count of 433 cells/ul and HIV viral 
load of 1285 copies/ml. He was given a new course of induction chemotherapy with 
mitoxantrone, cytosine arabinoside but he failed to achieve remission. An immediate 
course of reinduction was repeated with mitoxantrone and cytosine arabinoside, after 
which he successfully achieved remission. He went on to receive a further 2 cycles of 
consolidation chemotherapy. This period of remission was maintained for 15 months 
on maintenance oral therapy with mercaptopurine, methotrexate and ATRA.  
 
In September of 2002, only 2 months after maintenance therapy was discontinued, 
11% promyelocytes were detected on a full blood count during a routine follow up 
visit. He was treated for this relapse with a combination of daunorubicin, cytosine 
arabinoside and ATRA, followed by one cycle of consolidation with mitoxantrone 
and cytosine arabinoside. The patient remained well for 8 months. 
 
In June of 2003, the patient was readmitted with a 3-day history of headache, fever 
and confusion. Clinically he was noted to have oral candidiasis, nuchal rigidity and 
pyrexia. The cerebrospinal fluid analysis was in keeping with a mixed meningitis with 
features of both bacterial and mycobacterial infection.  On this admission his CD4 
count was 174 cells/ul. The patient was subsequently started on intravenous 
antibiotics and empiric anti-TB treatment. Unfortunately, his neurological status 
deteriorated when he developed a hemiplegia. Computerized tomography of the brain 
revealed marked basal meningeal enhancement with a focal area of possible cerebritis 
in the left posterior aspect of the temporal lobe.  A repeat analysis of the cerebrospinal 
fluid revealed a marked lymphocytosis of 634 cells/ul and a protein level of 3.2 g/l. 
The patient showed a poor response to treatment and subsequently succumbed to 
progression of the disease and associated complications in July of 2003, a month after 
his second relapse and a total of 38 months from the initial diagnosis of AML. 
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3.16.6. Patient 6 
A 39-year-old female who was known to be HIV seropositive, and on antiretroviral 
therapy receiving a combination of zidovudine, lamivudine and nevirapine. She was 
previously diagnosed and treated in 1997 for biopsy proven Kaposi sarcoma of the 
lung. Etoposide was part of the chemotherapeutic regimen.  She presented in February 
of 2000 with symptoms of anaemia and bleeding (epistaxis, gum bleeding and easy 
bruising). On examination, she was pale and had oral candidiasis. She was also noted 
to have a pelvic mass that was thought to be of uterine origin on clinical examination. 
The initial FBC revealed a WCC of 3.4 x109/l, haemoglobin of 8.9 g/dl and a platelet 
count of 28 x109/l, with 14% blasts noted on the peripheral blood.  Her CD4 count at 
presentation was 193 cells/ul and her HIV viral load was >750 000 copies/ml. The 
bone marrow aspirate and trephine biopsy revealed extensive marrow infiltration by 
an acute myeloid leukaemia fitting best with acute promyelocytic leukaemia. The 
FISH analysis was positive for the PML/RARA fusion gene, with the flow cytometry 
also in keeping with AML (M3).  
 
The patient was given all-transretinoic acid (ATRA) and blood products for the 
worsening cytopenias. A trans-abdominal ultrasound revealed a large multi-loculated 
complex fluid collection with enhancement of the walls of the rectum and bladder in 
keeping with a retroperitoneal haematoma. This was initially treated conservatively 
with colpocentesis, however the haematoma continued to expand causing rectal and 
bladder compression necessitating evacuation by laparotomy. Unfortunately, the 
patient had a complicated post-operative course with abdominal sepsis and septic 
shock. Despite inotropic support and appropriate intravenous antibiotics, the patient 
demised in March 2000, a month after her initial diagnosis of AML.  
 
A summary of all the HIV seropositive patients with AML who were included as a 
case series can be found in table 3.12 below, and a summary of all the HIV 
seropositive patients with AML who were diagnosed and treated at Chris Hani 
Baragwanath hospital from 01/01/1993-31/12/2014 is included as table 3.13 below.  
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Table 3.12. Case reports: HIV seropositive patients with AML from 1993-2004   Patient	Age/Gender	(M/F)	 Duration	between	HIV	and	AML	diagnosis	(mths)	
Clinical	presentation	 Clinical	examination	 Laboratory	results	WCC	x109	Hb	g/dl	PLTS	x109	Blast	%	
FAB	subtype/	Marrow	features			
CD4	count	/HIV	viral	Load	
Treatment	/cART	 Outcome/survival	(days/mths)	 Cause	of	death	
Patient	1		22,	M	 0	 Symptoms	of	anaemia,	weight	loss,	night	sweats	
Shotty	generalized	LAD,	mild	hepatomegaly	
0.53	6.6	25	N/A	
MO	Hypercellular,	75-80%	blasts	 N/A	 Mitoxantrone		Not	given	cART	 Demised			Survival:	1	mth		 Severe	cytopenias.	Neutropenic	sepsis	Haemorrhagic	VZV	
Patient	2	37,	F	 8	 Nausea	and	vomiting,	weight	loss,	night	sweats,	dry	cough	
Shotty	cervical	and	inguinal	LAD,	gum	hypertrophy,	4cm	hepatomegaly	
24	5.9	13	60%	
M1	Extensive	leukaemic	infiltration	
N/A	 Cytosine	arabinoside			Not	given	cART	 Demised		Survival:	5	days	 Progressive	leukaemia	
Patient	3	38,	M	 0	 Symptoms	of	anaemia,	fever,	cough,	weight	loss,	night	sweats	
Pyrexial,	oral	candidiasis	 3.8	6	10	89%	
M2	 N/A	 Induction	1	and	consolidation1:	mitoxantrone			Induction	2:	mitoxantrone	Induction	3:	etoposide+cytosar	Palliative:	cytosar	Not	given	cART	
Demised			Survival:	17	mths	 Nosocomial	pneumonia	
Patient	4	18,	F	 0	 Bleeding:	haematemesis,	epistaxis	bleeding	gums	
Axillary	LAD	 2.7	9.2	434	N/A	
M3	Hypercellular	with	abnormal	promyelocytes	
410	N/A	 ATRA		Not	given	cART	 Lost	to	follow	up,	in	remission.			Survival:	2mths	
-	
	 60	
Patient	Age/Gender	(M/F)	 Duration	between	HIV	and	AML	diagnosis	(mths)	
Clinical	presentation	 Clinical	examination	 Laboratory	results	WCC	x109	Hb	g/dl	PLTS	x109	Blast	%	
FAB	subtype/	Marrow	features			
CD4	count	/HIV	viral	Load	
Treatment	/cART	 Outcome/survival	(days/mths)	 Cause	of	death	
Patient	5	30,	M	 0	 Sore	throat	gum	bleeding,	symptoms	of	anaemia	
Purulent	tonsillitis	 70	6.1	33	90%	
M3	Extensive	infiltrate	of	89%	promyelocytes	FISH	t(15;	17)			
554	37300	 Induction	1+	3	cycles	of	consolidation:	daunorubicin+cytosar+ATRA		New	course:	reinduction	mitoxantrone+cytosar	Maintenance	with	MMA			New	course:	reinduction	daunorubicin+cytosar+ATRA	Consolidation	mitoxantrone	and	cytosar.		cART	
Achieved	remission,	relapsed	after		3	mths	Achieved	remission,	relapsed	after		15	mths		Achieved	remission,	relapsed		after		8	mths	Demised		Survival:	38	mths	
Complicated	Mixed	meningitis		(bacterial	and	tuberculous)	
Patient	6	39,	F	 36		 Treated	previously	for	Kaposi’s	Sarcoma	with	etoposide	containing	regimen.	Symptoms	of	bleeding:	epistaxis,	gum	bleeding	
Oral	candida	Pelvic	mass	 3.4	8.9	28	14%	
M3	Abundant	promyelocytes	FISH:	t	(15,	17)	
193	>750	000	 ATRA		cART:	zidovudine+lamivudine+	nevirapine	
Demised			Survival:	1mth	
Surgical	complications:	intra-abdominal	sepsis		
cART= combination antiretroviral therapy, LAD= lymphadenopathy, N/A= not available, VZV= varicella zoster virus, Cytosar=cytosine arabinoside, mth(s)= month(s), ATRA= all-transretinoic acid, MMA: 
mercaptopurine+methotrexate+ATRA,FISH=fluorescent-in-situ hybridizaton
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Table 3.13. Summary of HIV seropositive patients with AML 
Parameter HIV seropositive patients 1993-2014 
N=33  
Age (mean)  37 years (range: 18-74 years) 
Gender  
Male 14 (42.4%) 
Female 19 (57.6%) 
Male: female ratio 1:1.4 
Symptoms  
Anaemia 29 (93.5%) 
Bleeding 16 (53.5%) 
  Bleeding gums 12 (75%) 
              Skin 6 (37.5%) 
Epistaxis 7 (43.8%) 
Malaena 2 (12.5%) 
Menorrhagia 4 (25%) 
Haemoptysis 1 (6.3%) 
Haematuria 1 (6.3%) 
Haematemesis 1 (6.3%) 
Infections 9 (27.3%) 
Respiratory 8 (88.9%) 
Gastrointestinal 1 (11.1%) 
Central nervous system 1 (11.1%) 
Constitutional symptoms  
Weight loss 19 (57.6%) 
Fever 21 (63.6%) 
Night sweats 18 (54.5%) 
Bone pain 5 (16.7%) 
Clinical signs   
Pallor 31 (93.9%) 
Lymphadenopathy 12 (36.4%) 
Signs of bleeding  
Ecchymosis 11 (33.3%) 
Petechiae 7 (21.2%) 
Purpura 5 (15.2%) 
Evidence of infection  
Respiratory 11 (91.7%) 
Genitourinary 1 (8.3%) 
Central nervous system 1 (9.0%) 
Tuberculosis 7 (22.6%) 
Organomegaly  
Hepatomegaly 13 (39.4%) 
Splenomegaly 6 (18.2%) 
Abdominal mass 2 (6.1%) 
Extramedullary  
Gum hypertrophy 3 (9.1%) 
Myeloid sarcoma 3 (9.1%) 
Skin 2 (6.1%) 
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Parameter HIV seropositive patients 1993-2014 
N=33  
De novo versus secondary aetiology  
De novo (primary) 29 (87.9%) 
Secondary 4 (12.1%) 
Myelodysplasia 2 (6.1%) 
Chemotherapy related 2 (6.1%) 
FAB histological subtype  
M0 2 (7.7%) 
M1 1 (3.8%) 
M2 11 (42.3%) 
M3 10 (38.5%) 
M4 2 (7.7%) 
M5/M6/M7 0  
Unknown 7 
CD4 cells/ul (mean) 350 (range: 29-1379) 
HIV viral load copies/ml (mean)  185 265 (range: 0-750 000) 
Management  
Received chemotherapy  
Yes 26 (78.8%) 
No 7 (21.2%) 
Maintenance chemotherapy 4 (12.1%) 
Palliative chemotherapy 3 (9.1%) 
Combination antiretroviral therapy 20 (60.6%) 
Outcome  
Alive 0  
Demised 27 (81.8%) 
Lost to follow up 6 (18.2%) 
Survival (median in years) 0.3 years. 
FAB = French American British classification.   
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CHAPTER 4: DISCUSSION 
4.1 Demographics of AML 	
Acute myeloid leukaemia is a haematological malignancy that occurs mainly in the 
elderly. Due to its demographics, it occurs less frequently in the setting of HIV 
infection. In this study the records of 189 patients with AML were reviewed over a 
ten-year period from 01/01/2005 to 31/12/2014, with an additional 6 HIV seropositive 
patients with AML reviewed for the period from 01/01/1993 to 31/12/2004. An 
overwhelming majority of patients in the study population were of Black African 
decent, which represents the patient demographic of Chris Hani Baragwanath 
Academic Hospital. There was a predominance of men compared to women in this 
study, with a male: female ratio of 1.1:1, which is in keeping with the known male 
predominance in AML (1). Interestingly, the HIV seropositive group demonstrated a 
female predominance of 59% with a male: female ratio of 1:1.5. This reflects the 
demographics of HIV in Sub-Saharan Africa, which carries 70.8% of the global 
burden of HIV, and 57% of this HIV seropositive population are females (39). 
 
 
The median age at presentation in this study population was 45 years (IQR 18-88 
years). The age at presentation in our study is lower than what has been reported in 
the literature i.e. the seventh decade of life with an average of 67-70 years (1, 5). A 
similar younger age of AML of 41 years was also found in a study carried out by 
Marshall et al., at the National Health Laboratory Services (NHLS), at the University 
of the Witwatersrand. In the HIV seropositive patients with AML, the age at 
presentation was statistically significantly lower, at a median of 38 years (p-value of 
0.027). This is largely attributable to the general trends of HIV seropositive patients in 
the South African setting, where the highest incidence of HIV as a cause of disability 
is seen in patients between the ages of 30-44 years (39). Haematological malignancies 
occurring in HIV seropositive patients have been documented in younger age groups 
although these have been mainly of the lymphoid lineage (29, 30). Furthermore, the 
demographics of the HIV seropositive population in South Africa are different from 
that encountered in Europe and the Americas where the HIV seropositive population 
is comprised mainly of older homosexual male patients. This may account for the 
HIV seropositive AML patients encountered in our study being predominantly 
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younger females and where the predominant risk factor for HIV infection is typically 
heterosexual contact. 
 
4.2. Aetiopathogenesis of AML 
 
In the aetiopathogenesis of AML in this study, the most common risk factor identified 
for AML was occupational exposure found in 5% of patients. Patients who were 
previously treated for a malignancy with exposure to cytotoxic drugs comprised 3.7% 
of the patients in our study. Although de novo AML predominated, secondary AML 
was documented in 31% of the total study population. The HIV seronegative AML 
patients were statistically significantly more likely to develop secondary AML than 
their HIV seropositive counterparts (p-value 0.016). The most common aetiology of 
secondary AML in this study population was pre-existing myelodysplasia with 
leukaemic transformation, being present in 51% of patients with secondary AML. 
There was no difference in the incidence of myelodysplasia between the HIV 
seronegative and HIV seropositive patients. The evolution of secondary AML from 
myelodysplastic syndromes is well documented and occurs as a progression of disease 
in up to a third of patients (44, 45). A possible reason that has been cited for AML 
occurring in the setting of HIV infection includes the interaction of the human 
immunodeficiency virus with the marrow micro-environment which may affect 
cellular proliferation and potentially lead to myelodysplasia and malignant 
transformation (36). The features of HIV related myelodysplasia were found in only 
one patient in this study and remains an extremely rare cause of AML in this setting.  
 
Myeloproliferative disorders, in particular chronic myeloid leukaemia (CML) 
undergoing blastic transformation was responsible for 39% of secondary AML. The 
incidence of patients who develop AML following a course of chemotherapy, with 
either an alkylating agent or topoisomerase II inhibitor, has been cited to be as high as 
10-15% in some studies (1, 44). In this study, however, the incidence of therapy 
related AML was very low, at 3.7% of the overall study population.  
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4.3. Clinical presentation of patients with AML 
 
Patients are typically referred to us with AML following the detection of blasts on the 
peripheral blood smear. The clinical presentation in these patients is usually with 
symptoms of bone marrow failure/infiltration. This is the most commonly described 
clinical presentation of AML in the literature (1, 40). The prevalence of symptoms of 
anaemia, bleeding and infections was similar for the HIV seronegative and HIV 
seropositive groups. Symptoms of anaemia are the most common presenting feature, 
present in 92 % of the patients; this correlates with pallor/anaemia, being the most 
common clinical sign in 94% of the patients.  
 
With regard to infections as a presenting feature, the respiratory tract was the most 
common site of infection (68%). There was a correlation between reported symptoms 
and the clinical evidence of infections across the organ systems with the exception of 
central nervous system infections which were more likely to be detected clinically due 
in part to the inability of the patient to accurately report these symptoms. Although 
there was no difference in the incidence of acute infections between the two study 
populations, the proportion of patients with tuberculosis was higher in the HIV 
seropositive patients with AML, compared to their HIV seronegative counterparts. 
This difference was statistically significant with a p-value of 0.0018. In the 16 
patients with tuberculosis, pulmonary TB was the most common site of infection, 
while in 4 patients the diagnosis of tuberculosis was made on the presence of 
tuberculous bacilli on a bone marrow specimen submitted for the purpose of 
confirmation of the AML diagnosis. The symbiotic relationship between HIV and TB 
is well documented and tuberculosis remains the most common cause of mortality and 
morbidity among the HIV seropositive population of Southern Africa (39). 
 
4.4. Extramedullary disease 
 
It has been proposed that extramedullary disease in AML may occur more commonly 
in patients who are HIV seropositive, similar to extranodal disease occurring more 
commonly in HIV infected patients with lymphoproliferative malignancies (36, 40). 
Although the incidence of extramedullary disease was higher in this study at 21% of 
the overall population than found in other studies in the literature, the incidence of 
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extramedullary disease was no higher in the HIV seropositive patients compared to 
the HIV seronegative patients with AML.  
 
Myeloid sarcoma in this study population occurred in 13/189 (6.9%) of the patients. 
Among the patients presenting with a myeloid sarcoma, only 3 were HIV 
seropositive. The presentation of a myeloid sarcoma is rare in AML; its incidence in 
AML ranges between 1-9.1% (1, 46). In view of the atypical and aggressive course 
that haematological malignancies tend to follow in HIV infection, it has been 
proposed that myeloid sarcomas may occur with a higher incidence among HIV 
seropositive patients with AML (36). This however, has not been conclusively shown 
in published studies. In our study, we were unable to show any statistically significant 
difference in the incidence of myeloid sarcomas between the HIV seropositive and 
seronegative patients.  
 
Involvement of the reticuloendothelial system with the presence of lymphadenopathy, 
hepatomegaly and splenomegaly may be a clinical feature of uncomplicated HIV 
infection, thus it may be expected that HIV seropositive patients with AML may have 
a higher incidence of these clinical signs at presentation. This, however, was not a 
significant finding in this study. Generally these features are less commonly 
encountered in the setting of AML, than in the lymphoproliferative disorders. 
 
4.5. Clinical presentation of HIV seropositive patients with AML 
 
This study contains the largest case series of HIV seropositive patients with AML 
seen and treated at a single center. A total of 33 HIV seropositive patients with AML 
were evaluated at the Clinical Haematology unit at Chris Hani Baragwanath 
Academic hospital. In the majority of patients in this study (60%), the diagnosis of 
HIV was made simultaneously with the AML diagnosis, with these patients being 
antiretroviral treatment naïve. This differs from international data where most patients 
reported are older with an antecedent diagnosis of HIV, and are on antiretroviral 
therapy prior to the diagnosis of AML. Only a small number of HIV seropositive 
AML patients presented with clinically advanced HIV disease or AIDS, with 3 HIV 
seropositive patients having WHO clinical stage 4 disease, based on the presence of 
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extra-pulmonary tuberculosis. Indeed, infection with tuberculosis was the most 
evident complication of HIV infection that was noted in this study. Pulmonary and 
extra-pulmonary tuberculosis occurred with a higher incidence in the HIV 
seropositive patients, this finding was statistically significant with a p-value =0.0018.  
 
 
The mean CD4 count among HIV seropositive AML patients was 353 cells/ul (range 
29-1379); predictably the CD4 counts were lower among patients not on cART. 
Nevertheless, the CD4 counts appear higher in our patients with AML than in a 
general HIV seropositive population and may be overestimated due to the leukaemic 
nature of the disease manifesting with higher leucocyte counts at presentation. The 
infection of haemopoietic progenitor cells by the human immunodeficiency virus, as a 
cause of leukaemogenesis in AML has never been proven, however it has been 
postulated that the degree of immunosuppression and depletion of T-lymphocytes 
caused by HIV significantly reduces immune surveillance and thus the clearance of 
leukaemic cells. This may be a risk factor not only for developing AML but may 
result in poorer outcomes in patients who are infected with HIV and particularly those 
with lower CD4 counts < 200 cells/ul (40). 
 
Eleven of the 12 the patients that had a preceding diagnosis of HIV infection were 
already on cART prior to developing AML, with a mean CD4 count of 310 cells/ul 
(range 156-505) and a mean duration of therapy of 24 months (range 0.7-84 months). 
Only one patient required a change in the antiretroviral therapy regimen due to an 
adverse drug reaction. In the case series of 6 patients, 4 out of 6 patients were not on 
cART due to the limited availability of antiretroviral therapy in South Africa prior to 
the launching of the national treatment programme in 2004 (47).  
 
4.6. Laboratory results 
 
In the HIV seropositive patient the presence of cytopenias is not infrequent. The 
aetiology of the cytopenias is often multifactorial, with anaemia of chronic disease, 
presence of opportunistic infections, nutritional factors as well as adverse drug effects 
being possible risk factors. Regarding the full blood count, the HIV seropositive 
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patients with AML had lower overall leucocyte, haemoglobin and platelet counts 
when compared to their HIV seronegative AML counterparts. Although the findings 
were not statistically significant for any of these parameters, it is accepted that HIV 
seropositive patients have a higher incidence of cytopenias in the setting of AML. 
When present however, cytopenias may be assumed to be due to other causes and this 
may delay the investigation and subsequent diagnosis of AML in patients who are 
HIV infected (36). 
 
Serum albumin was statistically significantly lower in the HIV seropositive (mean 
31.4 g/l) compared to the HIV seronegative AML patients (mean 35.4 g/dl), p-value 
of 0.0064. Albumin is a well-known negative acute phase reactant, it tends to be low 
in the setting of chronic inflammation, protein and energy malnutrition and 
malabsorptive states, all of which can occur in the setting of HIV infection. With 
regards to haematinic levels, the HIV seronegative patients had higher ferritin levels 
compared to the HIV seropositive patients, this difference was significant with a p-
value of 0.034. The elevated ferritin levels may reflect an acute inflammatory 
response to infections or the leukaemic process itself. The ferritin levels may 
therefore not be an accurate measure of iron stores in these patients. Further subgroup 
analysis of biochemistry parameters revealed that the HIV seropositive patients with 
AML had lower serum sodium and gamma glutamyl transferase levels compared to 
the HIV seronegative patients, the reason for these findings are unclear and may need 
to be explored in future studies.  
 
4.7.  Marrow elements 
 
The presence of cellular dysplasia during histological evaluation of the bone marrow 
aspirate and trephine samples was reported in 30% of HIV seronegative AML 
samples and 26% of HIV seropositive AML samples. In the HIV seropositive group 
only one sample was noted to have HIV related myelodysplastic changes. This 
represents less than 4% of the total HIV seropositive study group. These findings 
confirm the notion that despite HIV related marrow dysplasia being an important 
cause of HIV related cytopenias, the progression of this dysplasia to overt leukaemia 
is still exceptionally rare (36).  
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4.8.  Histological subtypes and cytogenetics 
 
Overall, the most common histological subtype was AML M2 (myeloblastic with 
granulocytic maturation), being present in 25% of the study population. Indeed, AML 
M2 was more common in the HIV seropositive group, being present in 48% of these 
AML patients. The predominance of AML M2 in HIV seropositive patients has also 
been demonstrated in other studies (36, 40). Acute promyelocytic leukaemia – AML 
M3 was the next most common subtype representing 22% of the population. The high 
incidence of AML M3 is however, a unique finding in our study and may reflect the 
younger age at presentation of AML M3 patients with a mean age of 32 years (range: 
16-57 years), coinciding with the younger age at presentation of HIV seropositive 
patients with a mean age of 39 years (range: 21-74 years). 
 
With regard to cytogenetics, the most common favourable cytogenetic abnormality 
was translocation (15; 17), found in 96% of the patients with AML M3 subtype. There 
was no difference between HIV seropositive and HIV seronegative patients in this 
regard. The HIV seropositive patients with the AML M2 subtype in our study were 
more likely to express the favourable translocation (8; 21) cytogenetic abnormality 
when compared to the HIV seronegative AML M2 patients. This difference was 
statistically significant with a p-value of 0.0091. The inversion (16) cytogenetic 
abnormality, which is also viewed as a favourable cytogenetic abnormality was rare in 
this study population, with an overall prevalence of 2.4%. 
 
Unfavourable cytogenetics occurred at a lower incidence in our study population. The 
most common unfavourable cytogenetic abnormality found in this study was 
translocation (9; 22), which occurred in 6.6% of the patients with presumed blastic 
transformation from chronic myeloid leukaemia to acute myeloid leukaemia. A 
complex karyotype, which is defined as the presence of at least 3 chromosomal 
abnormalities within a malignant cell (2), was found in 5 patients (3%). Only one of 
these patients was HIV seropositive. The chromosomal deletions, 7q- and 5q- were 
also infrequent, with a frequency of 6% and 2.4%, respectively. Abnormalities in 
chromosome 7 tend to be associated with myelodyplasia as well as chemotherapy 
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related AML. In our study, only one patient with previous exposure to cytotoxic 
agents displayed this abnormality. The presence of unfavourable cytogenetic 
abnormalities were no different in the HIV seronegative compared to the HIV 
seropositive group of AML patients. The low levels of unfavourable cytogenetics 
could again be due to the younger age of the patients in our study. The highest risk for 
unfavourable cytogenetic abnormalities in AML includes advanced age; therapy 
related AML as well as AML that evolves from a preceeding myeloproliferative 
neoplasm (11, 22). 
 
4.9.  Treatment and therapeutic response 
 
In the treatment of AML, the chemotherapy regimen for remission induction has 
remained essentially unchanged over the past few decades with the combination of an 
anthracycline and cytosine arabinoside forming the backbone of treatment and serving 
as the standard of care for initial therapy (1, 2). In our study, 82% of the patients 
treated for AML received the standard induction chemotherapy. The majority of these 
patients (60%) received the standard “3+7” regimen. There were a lower proportion 
of HIV seropositive patients with AML (35%), who received the standard seven days 
of cytosine arabinoside when compared to the HIV seronegative patients with AML 
(65%). This difference between the two study populations was statistically significant 
with a p-value of 0.0015. The HIV seropositive AML patients in this study were more 
likely to receive a reduced duration of five days of cytosine arabinoside. This was 
largely due to more severe cytopenias and the greater potential for neutropenic 
complications.  
 
In all of the patients treated, 61% achieved a remission after the first cycle of 
chemotherapy, while 39% of the patients who received the first cycle of induction 
chemotherapy failed to achieve remission. In the subgroup analysis of patients who 
failed induction chemotherapy, 62.5% were HIV seronegative and 37.5% were HIV 
seropositive. This difference was not statistically significant with a p-value of 0.054. 
This finding supports the fact that HIV seropositive patients treated intensively for 
AML are not more likely to fail induction chemotherapy and can therefore achieve 
similar remission rates as their HIV seronegative counterparts (29, 36, 40).  
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In patients who required further cycles of induction chemotherapy due to either 
relapsed or refractory disease, the most commonly administered regimen for re-
induction cycles 1 to 3 was a combination of mitoxantrone, etoposide and cytosine 
arabinoside. Patients with refractory disease, who went on to require reinduction 
chemotherapy beyond cycle 3, were given a combination of fludarabine and cytosine 
arabinoside, which is a conventional recommended regimen for salvage therapy. One 
patient with primary refractory disease was given 2 courses of azacitidine; this drug 
has been shown to improve survival in patients who are unlikely to tolerate 
conventional salvage therapies, particularly in the elderly patient (2, 3). 
 
With regard to consolidation chemotherapy, the most common regimen that was 
administered to patients who had achieved remission was a combination of 
daunorubicin with high dose cytosine arabinoside given over 1-2 hours, every 12 
hours over three days (a total of 6 doses). This regimen was given through 
consolidation cycles 1 to 4 in the first chemotherapy course. Patients with acute 
promyelocytic leukaemia (AML M3) were given consolidation chemotherapy with a 
combination of daunorubicin and all-transretinoic acid, which is the standard of care.  
 
Maintenance chemotherapy was only given to patients with the acute promyelocytic 
subtype of AML; all of these patients received a combination of mercaptopurine, all- 
transretinoic acid and methotrexate for a period of at least 2 years. A total of 36 
patients in this study were treated conservatively and given palliative chemotherapy 
due to a poor clinical condition. The majority of these patients were HIV 
seronegative, with advanced age, a poor performance status as well as severe 
cytopenias. Regarding patients who received palliative chemotherapy, oral 
thioguanine was most commonly administered in 89% of these patients, while 11% of 
the patients received low dose cytosine arabinoside as a single agent.  
 
In the setting of AML, palliative chemotherapy is generally given to control leukemic 
blast counts, when achieving a sustained remission with conventional intensive 
chemotherapy is not feasible. This is common practice for AML patients who are 
more elderly, have multiple co-morbid diseases or are clinically unfit (1). Although 
HIV seropositive patients are more likely to have disease processes that may render 
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them unsuitable candidates for intensive chemotherapy programmes, they have not 
been shown in the published literature or in our study to be more likely to receive 
palliative chemotherapy than their HIV seronegative counterparts.  
 
4.10.  Outcomes 
 
With regard to disease outcome in our study, 76% of patients demised, 18% of 
patients were lost to follow up, and 6% were alive at the time of the study. Of the 11 
patients that were alive at follow up, 10/11 patients were in remission and 1 patient 
had confirmed relapsed disease. A total of 34 patients in our study were lost to follow 
up, with 44% of these patients being in remission, while 38% of patients had 
refractory disease at their last clinic visit and may have possibly demised at home or 
at another health care facility. Of the patients that demised, and where the cause of 
death was known, the most common cause of death was neutropenic sepsis in both the 
HIV seronegative and seropositive patients. Neutropenic complications occurring as 
either progression of leukaemic disease or as a consequence of chemotherapy, is 
universally the most common cause of death among patients with AML (4). 
 
4.11.  Chemotherapy resistant AML 
 
Refractory AML was present in 38% of the overall population evaluated in this study. 
Forty-one out of 70 patients (59%) had primary refractory disease, having never 
achieved remission at any point in time during their treatment. The remaining 29 
patients (41%) with secondary refractory disease, who had previously achieved 
remission, and then subsequently relapsed, failed to respond to further cycles of 
chemotherapy. The incidence of refractory disease may reflect the incidence of 
secondary AML in our study. As previously stated, 31 % of patients in this study had 
secondary AML, the commonest aetiology of which was preceding myelodysplasia 
with leukaemic transformation. Myelodysplasia and therapy-related AML are more 
likely to be resistant to conventional chemotherapy than de novo AML (1). However, 
the majority of the patients with refractory disease in our study had de novo AML. 
This suggests that there may be molecular or genetic peculiarities in our AML 
population that contribute to chemo-resistance and which have not yet been explained 
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or properly clarified. The presence of an adverse cytogenetic abnormality and 
molecular aberrations are important predictors of chemotherapy resistant disease and 
adverse overall outcome in AML (1, 24, 48). Considering the predominance of 
favourable cytogenetic profiles detected in this study population, particularly in the 
HIV seropositive AML group, the incidence of chemotherapy resistant disease in this 
study population is higher than anticipated and further studies are needed to explain 
and assess the molecular and cytogenetic properties of AML, in the South African 
context. 
 
In the subgroup analysis, patients with refractory disease comprised 38% of the HIV 
seronegative patients with AML and 46% of the HIV seropositive patients with AML, 
respectively. Although patients with refractory disease comprised a higher proportion 
of the HIV seropositive group, the difference was not statistically significant, with a 
p-value of 0.39. HIV infection alone has not been shown to be an independent risk 
factor for developing chemotherapy resistant AML in our study. 
 
4.12.  Survival of patients with AML 
 
The overall survival of patients with AML in this study was dismal, with a median 
survival time of 4.8 months (95% confidence interval of 0.2-0.7 years). The poor 
survival is largely a reflection of the significant number of early deaths, within the 
first two to three months. Delays in referral, with more advanced disease at 
presentation are a major contributor in this group of patients with AML. This is 
supported by the improved survival rates when the survival analysis is performed 
excluding this group of patients with early mortality. There is a two-fold increase in 
the 1-year, 3-year and 5-year survival, respectively. There was however, no difference 
in survival rates between the HIV seronegative and HIV seropositive AML patients 
with a p-value of 0.4 (including early mortalities) and 0.98 (excluding early 
mortalities). Although there are many factors that may influence the survival of AML 
patients, it cannot be denied that resource limitations and general access to health care 
facilities remain ongoing challenges in the treatment of AML in the South African 
context. 
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4.13.  Limitations of the study 	
• Due to the retrospective nature of this study, the data collected was limited by 
missing and incomplete clinical and laboratory patient records.  
• Approximately 18% of the patients were lost to follow up.  
• The sample size of HIV seropositive patients was small, with only 33 patients 
being evaluated. This is primarily due to the rarity of AML occurring in HIV 
seropositive patients.  	  
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CHAPTER 5: CONCLUSION 
 
5.1.  Conclusion 
 
After the lymphomas and multiple myeloma, Acute Myeloid Leukaemia is the next 
most common haematological malignancy encountered in adults at Chris Hani 
Baragwanath Academic Hospital. Although HIV infection is seen in pandemic 
proportions at CHBAH, the association of AML and HIV infection is a rare 
occurrence. Nevertheless, the 33 HIV seropositive patients with AML in our study 
constitute the largest number of patients with this association diagnosed at a single 
center. However, direct comparisons were only made with regard to 27 HIV 
seropositive patients compared to HIV seronegative AML patients, during the period 
01/01/2005 to 31/12/2014. HIV seropositive patients with AML present at a younger 
age, with a female predominance. The clinical presentation is similar to that described 
in the literature with symptoms and signs of bone marrow failure/infiltration.  
 
In general, the HIV seropositive patients with AML had more profound cytopenias 
and a lower albumin level compared to their HIV seronegative counterparts. AML 
(M2) and AML (M3) were the most frequently encountered morphological subtypes 
of AML.  
 
The therapy of HIV seropositive patients with AML was similar to that in the HIV 
seronegative AML patients, with regard to both supportive as well as specific therapy. 
The HIV seropositive patients were more likely to receive a shorter course of cytosine 
arabinoside than their HIV seronegative counterparts. Complete remission was 
achieved in 60.7% of patients receiving induction chemotherapy. The HIV 
seropositive and HIV seronegative patients had similar remission rates. Chemotherapy 
resistant disease was present in 38% of the study population; the most prominent risk 
factor for refractory disease was secondary AML. HIV infection was not an 
independent risk factor for chemotherapy resistant disease.  
 
Overall the patient outcomes were as follows: 76% of the patients demised, 18% of 
patients were lost to follow up, and 6% were alive. The survival of AML patients at 6 
	 76	
months was 47% and 32.5% at 12 months. Patients who demised within the first 3 
months and who presented with advanced disease at presentation influenced the 
survival rates. Patient survival improved to 86.7% at 6 months and 60.1% at 12 
months, respectively, when the patients with early mortality were excluded.  
The current evidence suggests that acute myeloid leukaemia is a co-incidental 
malignancy in the setting of HIV infection, unlike high grade, B-cell Non-Hodgkin 
lymphoma, which is an AIDS defining malignancy. Despite there being no definite 
causal relationship between HIV and acute myeloid leukaemia, it is important to be 
aware of this association as there are differences between AML in seronegative and 
seropositive patients. Although similar chemotherapy is offered to both HIV 
seronegative and HIV seropositive patients, antiretroviral therapy is an important 
cornerstone of therapy in HIV seropositive patients with AML.  
 
We recommend future prospective studies with a greater focus on the aetiology, 
biology, clinical presentation, therapy, molecular and genetic characteristics of AML, 
in this uncommon population of HIV seropositivity coexisting with AML.  	  
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Appendix A: Data collection sheet 
Patient case number: ___________________ 
Date of birth: ___________________      Age:________ 
Gender__M______F_______         Ethnic group:__B__W__C____I_ 
Date of disease first documented (blasts on peripheral smear/BM/flow 
cytometry):_____Y_________N 
 
Clinical presentation (at diagnosis) 
 Yes No If yes, provide details  (onset, 
duration, severity) 
Anaemia    
Symptoms of anaemia    
Bleeding (site)    
Skin: easy bruising    
Epistaxis    
Gum bleeding    
Haemoptysis    
Haematemesis    
Malaena    
Haematuria    
Menorrhagia    
Infection    
Fever     
Source of sepsis    
• Respiratory  
• Genitourinary 
• GIT 
• Skin 
• Musculoskeletal  
• CNS 
 
   
Other     
	 81	
Night sweats    
Bone pain    
    
Previous history of malignancy    
Previous exposure to cytotoxic drugs    
Relevant drug history    
Occupational exposure: e.g. benzene, 
organic solvents 
   
 
HIV sero-positive patients 
Date of diagnosis: Day______        Month ______         Year______           
Baseline CD4 count:______ 
Clinical stage: ______ 
On  ART:  Y           N 
If yes, 
 
Duration on therapy (mths)   <6     6-12   12-24      24-36     36-48     48-60     >60     
Regimen changed: Y    N 
If yes: detail______________________________ 
 
Clinical examination (at diagnosis) 
 
General Yes No If yes, provide details (where relevant: 
duration, site, size, characteristics) 
Pallor    
Lymphadenopathy    
    
Bleeding    
Petechiae    
Purpura    
Ecchymosis    
Haemorrhagic bullae    
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Abdomen    
Hepatomegaly    
Splenomegaly     
Abdominal mass    
    
Extramedullary    
Gum hypertrophy    
Skin  
• Leukaemia cutis 
   
Myeloid sarcoma    
    
Infections    
Site of sepsis 
• Respiratory  
• Genitourinary 
• GIT 
• Skin 
• Musculoskeletal  
• CNS 
 
   
Positive blood cultures    
• Gram positive bacteria 
• Gram negative bacteria 
• Anaerobic organism 
• Fungal  
   
HIV associated opportunistic 
infections 
   
Tuberculosis    
Site 
• Pulmonary TB 
• TB abdomen 
• TB Meningitis 
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Treatment of AML 
 
Induction Consolidation Maintenance 
Cycle 1 
Regimen: 
a.  
b.  
c.  
d.  
1 2 3 4 5 6 >6 Y N 
Cycle 2 
 
       Y N 
Cycle 3        Y N 
Cycle 4        Y N 
Cycles > 4        Y N 
 
Outcome 
Alive: Y       N 
Survival (duration from diagnosis-current)  __________________ 
Current disease status:  remission _Y_____N__      Ongoing disease: Y    N 
If ongoing disease: duration,  remission was sustained______ , relapse 
 
Death:  Y   N 
Survival (duration from date of diagnosis- date of death):________ 
Documented cause/s of death: ____________ 
 
Lost to follow-up: 
Date of last clinic visit:_____ 
Status of disease at last visit: 
• Remission:                 Relapse:  
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Appendix B: Results flow chart 
 
Bone Marrow Aspirate 
&Trephine 
At 
diagnosis 
At 
remission 
End of 
consolidation 
Relapse 
(where 
relevant) 
Maintenance 
(where 
relevant) 
Morphology      
Cellularity 
• é 
• N 
• ê 
     
Blasts %  
• <20 
• 20-50 
• 50-80 
• >80 
• Specify blast 
count______ 
     
Background marrow 
elements 
     
Evidence of cellular 
dysplasia 
     
FAB subtype 
• MO 
• M1 
• M2 
• M3 
• M4 
• M5 
• M6 
• M7 
     
Flow cytometry 
• CD45 
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• CD 13 
• CD 14 
• CD 15 
• CD19 
• CD 34 
• CD 38  
• HLA DR 
• CD 16 
• CD 66 
Cytogenetics      
• t (15;17) 
• t(8;21) 
• inv(16) 
• 5q- 
• 7q- 
• t(9;22) 
• complex karyotype 
• FLT3 
• other 
     
      
WCC      
Hb      
Hct      
MCV      
PLT      
Neutro      
Mono      
Lymphs      
Eos      
Baso      
Ferritin      
Vit B12      
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Red cell folate      
Na      
K      
Chl      
Urea      
Creatinine      
LDH      
Uric acid      
Ca2+      
Mg      
PO4      
LFT: Tbili      
Cb      
Tprot      
Albumin      
ALP      
GGT      
AST      
ALT      
HIV 
• Negative 
• Positive 
• unknown 
     
Other:      
HIV+ Cases      
CD4      
HIVVL (RNA copies/ml)      
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Appendix C: Plagiarism ‘Turn-it-in’ Report 
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